TWI701055B - Tablet containing spherical adsorption carbon for oral administration and its manufacturing method - Google Patents

Tablet containing spherical adsorption carbon for oral administration and its manufacturing method Download PDF

Info

Publication number
TWI701055B
TWI701055B TW106110616A TW106110616A TWI701055B TW I701055 B TWI701055 B TW I701055B TW 106110616 A TW106110616 A TW 106110616A TW 106110616 A TW106110616 A TW 106110616A TW I701055 B TWI701055 B TW I701055B
Authority
TW
Taiwan
Prior art keywords
tablet
spherical
tablets
oral administration
volume ratio
Prior art date
Application number
TW106110616A
Other languages
Chinese (zh)
Other versions
TW201735906A (en
Inventor
町佳樹
神谷洋平
小野佐市
小西麻由
嶋田紘尚
Original Assignee
吳羽股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 吳羽股份有限公司 filed Critical 吳羽股份有限公司
Publication of TW201735906A publication Critical patent/TW201735906A/en
Application granted granted Critical
Publication of TWI701055B publication Critical patent/TWI701055B/en

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61JCONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/06Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of pills, lozenges or dragees
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/44Elemental carbon, e.g. charcoal, carbon black
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin

Abstract

本發明之目的係在於,提供一種口服給藥用球狀吸附炭之收穫率高,且口服給藥用球狀吸附炭及黏合用添加劑之均勻性高的片劑及其製造方法。上述課題可以透過下述片劑而解決,該片劑的特徵在於:規定的5個棱柱的每1mm3的添加劑體積率的最大值及最小值的比值為100以下;規定的3個分割體的立方體的體積率的相對標準偏差為5%以下;或者規定的5個棱柱的每1mm3的添加劑體積率的最大值及最小值的比值為100以下,且規定的3個分割體的立方體的體積率的相對標準偏差為5%以下。 The object of the present invention is to provide a tablet with high yield of spherical adsorbent carbon for oral administration, and high uniformity of spherical adsorbent carbon for oral administration and adhesive additives, and a manufacturing method thereof. The above-mentioned problem can be solved by the following tablet, which is characterized in that the ratio of the maximum value and the minimum value of the additive volume ratio per 1 mm 3 of the prescribed 5 prisms is 100 or less; The relative standard deviation of the volume rate of the cube is 5% or less; or the ratio of the maximum and minimum value of the additive volume rate per 1 mm 3 of the specified 5 prisms is 100 or less, and the volume of the cube of the specified 3 divisions The relative standard deviation of the rate is less than 5%.

Description

含口服給藥用球狀吸附炭的片劑及其製造方法 Tablet containing spherical adsorption carbon for oral administration and its manufacturing method

本發明有關於一種含口服給藥用球狀吸附炭的片劑及其製造方法。根據本發明,可提供一種收穫率優異的片劑之製造方法。 The present invention relates to a tablet containing spherical adsorbent carbon for oral administration and a manufacturing method thereof. According to the present invention, it is possible to provide a method for manufacturing a tablet having an excellent yield.

口服給藥用吸附劑可以口服,透過在消化道內吸附有害物質來治療腎功能障礙或肝功能障礙(專利文獻1)。為確保該口服給藥用球狀吸附炭發揮吸附有害物質的藥理效果,維持口服給藥用球狀吸附炭的球形,並維持其細孔結構很重要。該口服給藥用球狀吸附炭例如作為商品名「Kremezin(註冊商標)膠囊200mg」及「Kremezin(註冊商標)細粒分包2g」(以下稱作「Kremezin」)銷售。 The adsorbent for oral administration can be taken orally, and treats renal dysfunction or liver dysfunction by adsorbing harmful substances in the digestive tract (Patent Document 1). In order to ensure that the spherical adsorption carbon for oral administration exerts the pharmacological effect of adsorbing harmful substances, it is important to maintain the spherical shape of the spherical adsorption carbon for oral administration and maintain its pore structure. The spherical adsorption charcoal for oral administration is sold as a brand name of "Kremezin (registered trademark) capsule 200 mg" and "Kremezin (registered trademark) granular 2 g" (hereinafter referred to as "Kremezin"), for example.

對腎病患者的Kremezin每日投藥量為6g,將其分3次服用,每次服用量為2g。2g Kremezin細粒劑的體積約為4cm3,服用的體積絕對不少。因此,服用4cm3細粒劑時,球狀活性炭不溶解在水中,因而口腔內留有粗澀感,有些患者會不喜歡。 The daily dosage of Kremezin for patients with kidney disease is 6g, which is divided into 3 times, each dosage is 2g. The volume of 2g Kremezin granules is about 4cm 3 , and the volume to take is definitely a lot. Therefore, when taking 4cm 3 fine granules, the spherical activated carbon does not dissolve in water, so there is a rough feeling in the mouth, which some patients will not like.

另一方面,Kremezin膠囊劑不會在口腔內產生粗澀感。然而,膠囊劑中會形成球狀活性炭以外的無效體積,因此與細粒劑的體積相比,膠囊劑的體積約增加到1.5倍(約6cm3)。具體而言,體積 約0.613cm3的膠囊劑一次必須服用10粒,有些患者抱怨服用量太多。 On the other hand, Kremezin capsules do not produce roughness in the oral cavity. However, an ineffective volume other than the spherical activated carbon is formed in the capsule, so the volume of the capsule is approximately 1.5 times (about 6 cm 3 ) compared with the volume of the fine granule. Specifically, a capsule with a volume of about 0.613 cm 3 must be taken 10 capsules at a time, and some patients complain of taking too much.

此外,為消除細粒劑的粗澀感,或者由於膠囊劑服用量太多的緣故,很多患者服用細粒劑或膠囊劑時,不得不用大量水送服。腎病患者或腎功能不全患者中,有些患者需控制水分攝取量,這些患者服用細粒劑或膠囊劑等時,要求用盡量少的水送服,因而會對原本需要大量水送服的患者帶來巨大痛苦。 In addition, in order to eliminate the roughness of the fine granules, or due to the large amount of capsules taken, many patients have to use a lot of water when taking the granules or capsules. In patients with kidney disease or renal insufficiency, some patients need to control their water intake. When these patients take fine granules or capsules, they require as little water as possible, which will prevent patients who originally need a lot of water. Bring great pain.

【先行技術文獻】 【Advanced Technical Literature】 【專利文獻】 【Patent Literature】

【專利文獻1】日本專利特公昭62-11611號公報 [Patent Document 1] Japanese Patent Publication No. 62-11611

【專利文獻2】日本專利特開2006-8602號公報 [Patent Document 2] Japanese Patent Laid-Open No. 2006-8602

【專利文獻3】國際公開2012/121202號公報 [Patent Document 3] International Publication No. 2012/121202

為解決所述課題,可將口服給藥用球狀吸附炭製成片劑。然而,口服給藥用球狀吸附炭與普通藥物不同,不可通過壓縮等進行打片成型(專利文獻2)。即,口服給藥用球狀吸附炭與玻璃一樣,非常堅硬,缺乏變形性,具有易碎的性質,若對其進行打片成型,則口服給藥用球狀吸附炭被破壞,無法維持球形。 In order to solve the problem, the spherical adsorption carbon for oral administration can be made into tablets. However, the spherical adsorption charcoal for oral administration is different from ordinary drugs and cannot be tableted and molded by compression or the like (Patent Document 2). That is, the spherical adsorbent carbon for oral administration is very hard like glass, lacks deformability, and has a fragile nature. If it is punched and molded, the spherical adsorbent carbon for oral administration is destroyed and cannot maintain its spherical shape. .

本發明人等發現通過使用具有薄膜形成能力的顆粒製劑用添加劑的捏合法,可製造出能夠實際使用的含口服給藥用球狀吸附炭的 片劑(專利文獻3)。但是,採用捏合法製造片劑時,球狀活性炭之收穫率較低。此外,用捏合法獲得的片劑的口服給藥用球狀吸附炭及黏合用添加劑的均勻性較差。另外,用捏合法獲得的片劑的DL-β-胺基異丁酸的吸附量與顆粒剤或膠囊劑相比,可能降低。 The inventors of the present invention have discovered that by using a kneading method using an additive for granular preparations with film-forming ability, it is possible to produce practically usable spherical adsorbent carbon-containing materials for oral administration. Tablets (Patent Document 3). However, when using the kneading method to manufacture tablets, the yield of spherical activated carbon is low. In addition, the uniformity of the spherical adsorption carbon for oral administration and the additives for binding of tablets obtained by the kneading method is poor. In addition, the adsorption amount of DL-β-aminoisobutyric acid of tablets obtained by the kneading method may be lower than that of granules or capsules.

因此,本發明之目的係在於,提供一種口服給藥用球狀吸附炭之收穫率高,且口服給藥用球狀吸附炭及黏合用添加劑之均勻性高的片劑及其製造方法。 Therefore, the object of the present invention is to provide a tablet with high yield of spherical adsorbent charcoal for oral administration and high uniformity of spherical adsorbent charcoal for oral administration and adhesive additives, and a manufacturing method thereof.

本發明人對口服給藥用球狀吸附炭的收穫率較高且口服給藥用球狀吸附炭及黏合用添加劑的均勻性較好的片劑及其製造方法進行深入研究後,驚奇地發現,通過將含黏合用添加劑的溶液噴到或滴到口服給藥用球狀吸附炭上,採用壓縮成型法製造片劑,可獲得口服給藥用球狀吸附炭的收穫率得到飛躍改善,進而口服給藥用球狀吸附炭及黏合用添加劑的均勻性亦得到飛躍提高的片劑。 The inventors of the present invention conducted in-depth studies on tablets with high yield of spherical adsorbent carbon for oral administration and good uniformity of spherical adsorbent carbon for oral administration and binding additives and the manufacturing method thereof, and surprisingly found , By spraying or dropping the solution containing the adhesive additive onto the spherical adsorption carbon for oral administration, and manufacturing tablets by compression molding method, the yield rate of the spherical adsorption carbon for oral administration can be greatly improved, and then The uniformity of the spherical adsorption charcoal for oral administration and the additives for bonding has also been greatly improved.

本發明基於上述見解而得到。 The present invention was obtained based on the above knowledge.

因此,本發明有關於一種片劑以及片劑的製造方法。 Therefore, the present invention relates to a tablet and a method for manufacturing the tablet.

[1]一種片劑,其含有添加劑、以及口服給藥用球狀吸附炭,其特徵在於,用X射線CT顯微鏡對從上面觀察所述片劑時的中心部、以及位於從中心向四方延伸的直線端部的從上面到下面的邊長1mm的5個棱柱的添加劑的體積率從上面到下面進行解析時,5 個棱柱的每1mm3的添加劑體積率的最大值及最小值的比值為100以下。 [1] A tablet containing additives and spherical adsorption charcoal for oral administration, characterized in that the center portion of the tablet when observed from above with an X-ray CT microscope, and the location extending from the center to the four directions When analyzing the volume ratio of the additive of 5 prisms with a side length of 1mm from top to bottom at the end of the straight line from top to bottom, the ratio of the maximum and minimum volume ratio of the additive per 1mm 3 of the 5 prisms is Below 100.

[2]一種片劑,其含有添加劑、以及口服給藥用球狀吸附炭,其特徵在於,在將所述片劑的扁平方向長度分割成3等分的各分割體中,用X射線CT顯微鏡對位於扁平方向長度的中央且位於從上面觀察的片劑中心的邊長2mm立方體的體積率進行解析時,3個分割體的立方體的體積率的相對標準偏差為5%以下。 [2] A tablet containing additives and spherical adsorption charcoal for oral administration, characterized in that each divided body divided into three equal lengths in the flat direction of the tablet is subjected to X-ray CT When a microscope analyzes the volume ratio of a cube with a side length of 2 mm located at the center of the flat direction length and at the center of the tablet viewed from above, the relative standard deviation of the volume ratio of the cubes of three divided bodies is 5% or less.

[3]一種片劑,其含有添加劑、以及口服給藥用球狀吸附炭,其特徵在於,用X射線CT顯微鏡對從上面觀察所述片劑時的中心部、以及位於從中心向四方延伸的直線端部的從上面到下面的邊長1mm的5個棱柱的添加劑的體積率從上面到下面進行解析時,5個棱柱的每1mm3的添加劑體積率的最大值及最小值的比值為100以下;在將所述片劑的扁平方向長度分割成3等分的各分割體中,用X射線CT顯微鏡對位於扁平方向長度的中央且位於從上面觀察的片劑中心的邊長2mm立方體的體積率進行解析時,3個分割體的立方體的體積率的相對標準偏差為5%以下。 [3] A tablet containing additives and spherical adsorption charcoal for oral administration, characterized in that the center portion of the tablet when observed from above with an X-ray CT microscope, and the location extending from the center to the four directions When the volume ratio of the additive of 5 prisms with a side length of 1mm from top to bottom at the end of the straight line is analyzed from top to bottom, the ratio of the maximum and minimum additive volume ratios per 1mm 3 of the 5 prisms is 100 or less; in each of the divided bodies in which the length of the tablet is divided into 3 equal parts, an X-ray CT microscope is used to examine a cube with a side length of 2 mm located in the center of the length in the flat direction and at the center of the tablet viewed from above When analyzing the volume ratio of the three divided cubes, the relative standard deviation of the volume ratio of the cube is 5% or less.

[4]如[1]至[3]中任一項所述的片劑,其中,所述添加劑為選自由藻酸鈉、藻酸丙二醇酯、羧甲基纖維素、羧甲基纖維素鈣、茄替膠、角叉菜膠、羧基乙烯聚合物、羧甲基纖維素鈉、黃原膠、瓜爾豆膠、榅桲籽膠、葡甘露聚糖、共聚維酮、結蘭膠、明膠、羅望子膠、他拉膠、葡聚糖、玉米澱粉、黃蓍膠、透明質酸鈉、羥乙基纖維素、羥丙澱粉、羥丙基纖維素、羥丙甲纖維素、普魯蘭多糖、聚 維酮、聚環氧乙烷、聚乙烯醇、聚乙烯醇-丙烯酸-甲基丙烯酸甲酯共聚物、聚乙烯二醇6000、乙基纖維素、甲基纖維素、磷酸交聯澱粉、刺槐豆膠、瓊脂、寒梅粉、完全預膠化澱粉、結晶纖維素甲基纖維素鈉、氧化澱粉、低取代度羥丙基纖維素、部分預膠化澱粉、糖類、以及糖醇類所組成的組中的黏合用添加劑。 [4] The tablet according to any one of [1] to [3], wherein the additive is selected from sodium alginate, propylene glycol alginate, carboxymethyl cellulose, and calcium carboxymethyl cellulose , Ghatti gum, carrageenan, carboxyvinyl polymer, sodium carboxymethyl cellulose, xanthan gum, guar gum, quince seed gum, glucomannan, copovidone, gellan gum, gelatin , Tamarind gum, tara gum, dextran, corn starch, tragacanth gum, sodium hyaluronate, hydroxyethyl cellulose, hydroxypropyl starch, hydroxypropyl cellulose, hypromellose, pullulan Polysaccharides, poly Vividone, polyethylene oxide, polyvinyl alcohol, polyvinyl alcohol-acrylic acid-methyl methacrylate copolymer, polyethylene glycol 6000, ethyl cellulose, methyl cellulose, phosphoric acid cross-linked starch, locust bean Gum, agar, winter plum powder, fully pregelatinized starch, crystalline cellulose sodium methylcellulose, oxidized starch, low-substituted hydroxypropyl cellulose, partially pregelatinized starch, sugars, and sugar alcohols Adhesive additives in

[5]如[1]至[4]中任一項所述的片劑,其中,所述口服給藥用球狀吸附炭為球狀活性炭。 [5] The tablet according to any one of [1] to [4], wherein the spherical adsorption carbon for oral administration is spherical activated carbon.

[6]如[5]所述的片劑,其中,所述球狀活性炭的平均粒徑為0.02至1mm。 [6] The tablet according to [5], wherein the average particle diameter of the spherical activated carbon is 0.02 to 1 mm.

[7]一種片劑的製造方法,其特徵在於,包含:(1)將包含選自由藻酸鈉、藻酸丙二醇酯、羧甲基纖維素、羧甲基纖維素鈣、茄替膠、角叉菜膠、羧基乙烯聚合物、羧甲基纖維素鈉、黃原膠、瓜爾豆膠、榅桲籽膠、葡甘露聚糖、共聚維酮、結蘭膠、明膠、羅望子膠、他拉膠、葡聚糖、玉米澱粉、黃蓍膠、透明質酸鈉、羥乙基纖維素、羥丙澱粉、羥丙基纖維素、羥丙甲纖維素、普魯蘭多糖、聚維酮、聚環氧乙烷、聚乙烯醇、聚乙烯醇-丙烯酸-甲基丙烯酸甲酯共聚物、聚乙烯二醇6000、乙基纖維素、甲基纖維素、磷酸交聯澱粉、刺槐豆膠、瓊脂、寒梅粉、完全預膠化澱粉、結晶纖維素甲基纖維素鈉、氧化澱粉、低取代度羥丙基纖維素、部分預膠化澱粉、糖類、以及糖醇類所組成的組中的黏合用添加劑的溶液噴到或滴到口服給藥用球狀吸附炭上,用黏合用添加劑覆蓋口服給藥用球狀吸附炭的製程;(2)向被覆蓋的所述口服給藥 用球狀吸附炭添加溶媒,然後通過壓縮成型,獲得成型體的壓縮成型製程;以及(3)對獲得的成型體進行乾燥的製程。 [7] A method for manufacturing a tablet, characterized in that it comprises: (1) a compound selected from sodium alginate, propylene glycol alginate, carboxymethyl cellulose, calcium carboxymethyl cellulose, gum ghatti, keratin Chakra gum, carboxyvinyl polymer, sodium carboxymethyl cellulose, xanthan gum, guar gum, quince seed gum, glucomannan, copovidone, gellan gum, gelatin, tamarind gum, other Pull gum, dextran, corn starch, tragacanth, sodium hyaluronate, hydroxyethyl cellulose, hydroxypropyl starch, hydroxypropyl cellulose, hypromellose, pullulan, povidone, Polyethylene oxide, polyvinyl alcohol, polyvinyl alcohol-acrylic acid-methyl methacrylate copolymer, polyethylene glycol 6000, ethyl cellulose, methyl cellulose, phosphoric acid cross-linked starch, locust bean gum, agar , Winter plum powder, fully pregelatinized starch, crystalline cellulose sodium methylcellulose, oxidized starch, low degree of substitution hydroxypropyl cellulose, partially pregelatinized starch, sugars, and sugar alcohols Spray or drop the solution of additives onto the spherical adsorption carbon for oral administration, and cover the manufacturing process of the spherical adsorption carbon for oral administration with the adhesive additive; (2) To the covered oral administration The spherical adsorption carbon is used to add a solvent, and then compression molding is performed to obtain a compression molding process of the molded body; and (3) a process of drying the obtained molded body.

根據本發明的含口服給藥用球狀吸附炭(例如,球狀活性炭)的片劑的製造方法,可改善使用的口服給藥用球狀吸附炭的收穫率。此外,採用本發明的製造方法獲得的含口服給藥用球狀吸附炭的片劑可防止口服給藥用球狀吸附炭及黏合用添加劑的局部分佈,提高口服給藥用球狀吸附炭及黏合用添加劑的均勻性。因此,獲得的片劑的硬度得到改善。另外,上述片劑可示出優異的DL-β-胺基異丁酸的吸附能力。即,根據本發明的片劑的製造方法,與專利文獻3中記載的捏合法相比,可改善片劑的製造方法的口服給藥用球狀吸附炭的收穫率及硬度,還可期待改善DL-β-胺基異丁酸的吸附能力。 According to the method for manufacturing a tablet containing spherical adsorbent carbon for oral administration (for example, spherical activated carbon) of the present invention, the yield of the spherical adsorbent carbon for oral administration used can be improved. In addition, the tablet containing spherical adsorbent carbon for oral administration obtained by the manufacturing method of the present invention can prevent the local distribution of spherical adsorbent carbon for oral administration and adhesive additives, and improve the spherical adsorbent carbon for oral administration and The uniformity of bonding additives. Therefore, the hardness of the obtained tablet is improved. In addition, the above-mentioned tablet can show excellent adsorption capacity of DL-β-aminoisobutyric acid. That is, according to the tablet manufacturing method of the present invention, compared with the kneading method described in Patent Document 3, the yield and hardness of the spherical adsorption carbon for oral administration in the tablet manufacturing method can be improved, and it is also expected to improve DL -The adsorption capacity of β-aminoisobutyric acid.

根據本發明的片劑,可提供一種與膠囊劑相比能夠減少體積,且服用性得到改善的片劑。即,服用膠囊劑的情況下,體積約0.613cm3的膠囊劑一次必須服用10粒,有些患者抱怨服用量太多,對此,本發明的片劑可將體積減少到膠囊劑的65%(約4cm3),服用性提高。此外,根據本發明的片劑,可提供一種與細粒劑相比改善粗澀感等服用性缺點的片劑。根據本發明的片劑,可提供一種維持口服給藥用球狀吸附炭的球形,細孔結構不被破壞,且能夠充分發揮口服給藥用吸附劑功能的片劑。 According to the tablet of the present invention, it is possible to provide a tablet that can be reduced in volume compared with a capsule and has improved administrability. That is, in the case of taking capsules, 10 capsules with a volume of about 0.613 cm 3 must be taken at a time. Some patients complain that the dosage is too much. In this regard, the tablet of the present invention can reduce the volume to 65% of the capsule ( Approximately 4cm 3 ), the ease of use is improved. In addition, according to the tablet of the present invention, it is possible to provide a tablet that has improved ingestibility disadvantages such as roughness and astringency compared with fine granules. According to the tablet of the present invention, it is possible to provide a tablet that maintains the spherical shape of the spherical adsorption carbon for oral administration, does not destroy the pore structure, and can fully exhibit the function of the adsorbent for oral administration.

圖1是從上面(A)及側面(B)對在本發明的片劑中解析片劑體積率的3個立方體的位置進行示意的圖。 Fig. 1 is a diagram schematically showing the positions of three cubes for analyzing the tablet volume ratio in the tablet of the present invention from the upper surface (A) and the side surface (B).

圖2是示出用本發明的製造方法獲得的片劑(A)、以及用過去的捏合法獲得的片劑(B)的添加劑的局部分佈的X射線CT顯微鏡(nano3DX)的解析圖像。 2 is an X-ray CT microscope (nano3DX) analysis image showing the local distribution of additives in the tablet (A) obtained by the manufacturing method of the present invention and the tablet (B) obtained by the conventional kneading method.

圖3是從上面(A)及側面(B)對在本發明的片劑中解析添加劑體積率的5個棱柱的位置進行示意的圖。 Fig. 3 is a diagram schematically showing the positions of five prisms for analyzing the volume ratio of additives in the tablet of the present invention from the top (A) and the side (B).

圖4是示出用X射線CT顯微鏡對本發明的片劑的添加劑的體積率從上面到下面進行解析時的變化的曲線圖。 Fig. 4 is a graph showing the change when the volume ratio of the additive of the tablet of the present invention is analyzed from top to bottom using an X-ray CT microscope.

圖5是示出利用捏合法製造的球狀活性炭殘存在攪拌造粒機(A)、以及附著在成型模具(B)的照片。 Fig. 5 is a photograph showing that the spherical activated carbon manufactured by the kneading method remains in the stirring granulator (A) and adheres to the molding die (B).

圖6是基於256級亮度訊息對用解析軟體ImageJ計算添加劑的體積率時的添加劑與球狀活性炭進行區分的曲線圖以及照片。 Fig. 6 is a graph and a photograph of the difference between the additive and the spherical activated carbon when the volume ratio of the additive is calculated by the analysis software ImageJ based on the 256-level brightness information.

〔1〕含口服給藥用球狀吸附炭的片劑 [1] Tablets containing spherical adsorption charcoal for oral administration

本發明之含口服給藥用球狀吸附炭的片劑含有黏合用添加劑。上述黏合用添加劑,優選從藻酸鈉、藻酸丙二醇酯、羧甲基纖維素、羧甲基纖維素鈣、茄替膠、角叉菜膠、羧基乙烯聚合物、羧甲基纖維素鈉、黃原膠、瓜爾豆膠、榅桲籽膠、葡甘露聚糖、共聚維酮、結蘭膠、明膠、羅望子膠、他拉膠、葡聚糖、玉米澱粉、黃蓍膠、透明質酸鈉、羥乙基纖維素、羥丙澱粉、羥丙基纖 維素、羥丙甲纖維素、普魯蘭多糖、聚維酮、聚環氧乙烷、聚乙烯醇、聚乙烯醇-丙烯酸-甲基丙烯酸甲酯共聚物、聚乙烯二醇6000、乙基纖維素、甲基纖維素、磷酸交聯澱粉、刺槐豆膠、瓊脂、寒梅粉、完全預膠化澱粉、結晶纖維素甲基纖維素鈉、氧化澱粉、低取代度羥丙基纖維素、部分預膠化澱粉、糖類、以及糖醇類所組成之組中進行選擇。另外,上述口服給藥用球狀吸附炭優選為球狀活性炭。 The tablet containing spherical adsorption charcoal for oral administration of the present invention contains a binding additive. The above-mentioned adhesive additives are preferably selected from sodium alginate, propylene glycol alginate, carboxymethyl cellulose, calcium carboxymethyl cellulose, gum ghatti, carrageenan, carboxyvinyl polymer, sodium carboxymethyl cellulose, Xanthan gum, guar gum, quince seed gum, glucomannan, copovidone, gellan gum, gelatin, tamarind gum, tara gum, dextran, corn starch, tragacanth gum, hyaluronic acid Sodium, hydroxyethyl cellulose, hydroxypropyl starch, hydroxypropyl fiber Vitamin, hypromellose, pullulan, povidone, polyethylene oxide, polyvinyl alcohol, polyvinyl alcohol-acrylic acid-methyl methacrylate copolymer, polyethylene glycol 6000, ethyl Cellulose, methyl cellulose, phosphoric acid cross-linked starch, locust bean gum, agar, winter plum powder, fully pregelatinized starch, crystalline cellulose sodium methylcellulose, oxidized starch, low-substituted hydroxypropyl cellulose, part Choose from the group consisting of pregelatinized starch, sugars, and sugar alcohols. In addition, the spherical adsorption carbon for oral administration is preferably spherical activated carbon.

《口服給藥用球狀吸附炭》 "Spherical adsorption charcoal for oral administration"

口服給藥用球狀吸附炭只要是可用於醫療的口服給藥用球狀吸附炭,則並無特別限定,但優選為口服給藥用球狀活性炭,即,可內服用於醫療的球狀活性炭。另外,本說明書中,作為口服給藥用球狀吸附炭的示例,可能使用球狀活性炭進行說明。 Spherical adsorption carbon for oral administration is not particularly limited as long as it is medically usable spherical adsorption charcoal for oral administration, but it is preferably spherical activated carbon for oral administration, that is, spherical activated carbon for oral administration. Activated carbon. In addition, in this specification, as an example of spherical adsorption carbon for oral administration, spherical activated carbon may be used for description.

例如,本發明的片劑所含的球狀活性炭的平均粒徑並無特別限定,但優選為0.02至1mm,更優選為0.03至0.90mm,進一步優選為0.05至0.80mm。此外,所述球狀活性炭的粒徑(直徑)範圍優選為0.01至2mm,更優選為0.02至1.5mm,進一步優選為0.03至1mm。 For example, the average particle diameter of the spherical activated carbon contained in the tablet of the present invention is not particularly limited, but is preferably 0.02 to 1 mm, more preferably 0.03 to 0.90 mm, and still more preferably 0.05 to 0.80 mm. In addition, the particle diameter (diameter) of the spherical activated carbon is preferably 0.01 to 2 mm, more preferably 0.02 to 1.5 mm, and still more preferably 0.03 to 1 mm.

「球狀活性炭」的BET比表面積為100m2/g以上,但用於本發明的球狀活性炭的BET比表面積優選為500m2/g以上,更優選為700m2/g以上,進一步優選為1300m2/g以上,特別優選為1650m2/g以上。 The BET specific surface area of the "spherical activated carbon" is 100 m 2 /g or more, but the BET specific surface area of the spherical activated carbon used in the present invention is preferably 500 m 2 /g or more, more preferably 700 m 2 /g or more, and even more preferably 1300 m 2 /g or more, particularly preferably 1650 m 2 /g or more.

片劑所含的口服給藥用球狀吸附炭(例如,球狀活性炭)為維持其細孔結構,發揮吸附有害物質的藥理效果,其形態優選為維持口服給藥用球狀吸附炭的球形。即,由於毒性物質的吸附能力,例如選擇吸附率會受到直徑、平均粒徑、比表面積、以及指定細孔直徑範圍的細孔容積等的影響,因而優選為維持口服給藥用球狀吸附炭不破損且對直徑或平均粒徑造成影響的球形,並維持對比表面積、細孔容積造成影響的細孔結構。進而,通過維持球形,可防止便秘等副作用。 The spherical adsorption carbon for oral administration (for example, spherical activated carbon) contained in the tablet maintains its pore structure and exerts the pharmacological effect of adsorbing harmful substances, and its form is preferably a spherical shape that maintains the spherical adsorption carbon for oral administration. . That is, since the adsorption capacity of toxic substances, such as selective adsorption rate, is affected by the diameter, average particle diameter, specific surface area, and pore volume within a specified pore diameter range, it is preferable to maintain the spherical adsorption carbon for oral administration. A spherical shape that is not damaged and affects the diameter or average particle size, and maintains a pore structure that affects the contrast surface area and pore volume. Furthermore, by maintaining the spherical shape, side effects such as constipation can be prevented.

《添加劑》 "additive"

本發明之片劑中所使用之添加劑含有黏合用添加劑。透過含有黏合用添加劑,能夠得到均勻性高、且強度優異之片劑。 The additives used in the tablet of the present invention contain adhesive additives. By containing additives for bonding, tablets with high uniformity and excellent strength can be obtained.

本發明的片劑的特徵在於作為添加劑而含有所述黏合用添加劑,但還可以含有黏合用添加劑以外的添加劑(以下稱作「其他添加劑」)。即,本發明的片劑作為添加劑可以含有黏合用添加劑、以及其他添加劑,此外還可以只含有黏合用添加劑。換言之,用於本發明的添加劑可以由黏合用添加劑、以及其他添加劑構成,還可以由黏合用添加劑構成。 The tablet of the present invention is characterized by containing the above-mentioned adhesive additive as an additive, but may also contain additives other than the adhesive additive (hereinafter referred to as "other additives"). That is, the tablet of the present invention may contain an adhesive additive and other additives as an additive, and may also contain only an adhesive additive. In other words, the additives used in the present invention may be composed of adhesive additives and other additives, and may also be composed of adhesive additives.

(添加劑的含量) (Content of additives)

口服給藥用球狀吸附炭(例如,球狀活性炭)與添加劑的重量比只要可獲得本發明的效果,則並無特別限定,例如添加劑優選為1至35重量%,更優選為1.5至35重量%,進一步優選為2至35重量%。口服給藥用球狀吸附炭與添加劑的重量比在上述範圍內的情況下,能夠得到均勻性高的片劑。在添加劑的量過少的情況下,有時難以形成片劑。另外,如果添加劑過多,則可能片劑體積較大,片劑服用量較多。 The weight ratio of the spherical adsorbent carbon for oral administration (for example, spherical activated carbon) to the additive is not particularly limited as long as the effect of the present invention can be obtained. For example, the additive is preferably 1 to 35% by weight, more preferably 1.5 to 35. % By weight, more preferably 2 to 35% by weight. When the weight ratio of the spherical adsorbent carbon for oral administration to the additive is within the above range, a tablet with high uniformity can be obtained. When the amount of the additive is too small, it sometimes becomes difficult to form a tablet. In addition, if there are too many additives, the volume of the tablet may be larger and the dosage of the tablet may be larger.

《片劑的體積率的均勻性》 "Uniformity of Volume Rate of Tablets"

本發明的片劑之片劑內的體積率均勻。即,本發明的片劑與將普通化合物作為有效成分的片劑相比時,含有口服給藥用球狀吸附炭(例如,球狀活性炭)作為有效成分,因此根據圖1等可明確得知,口服給藥用球狀吸附炭彼此之間存在空隙。如果存在該空隙密集的部分及空隙稀疏的部分,則片劑的硬度或磨損度等可能降低。換言之,如果在片劑內由口服給藥用球狀吸附炭及添加劑構成的體積率存在不均勻,則片劑的硬度或磨損度等可能降低。即,片劑的體積率均勻,可提高片劑的硬度及磨損度等。 The tablet of the present invention has a uniform volume ratio in the tablet. That is, the tablet of the present invention contains spherical adsorbent carbon (for example, spherical activated carbon) for oral administration as an effective ingredient when compared with a tablet containing a common compound as an active ingredient. Therefore, it is clear from Fig. 1 etc. , There are gaps between the spherical adsorption carbon for oral administration. If there are portions with dense voids and portions with sparse voids, the hardness, abrasion, etc. of the tablet may decrease. In other words, if the volume ratio of the spherical adsorption carbon for oral administration and additives in the tablet is not uniform, the hardness, the degree of abrasion, etc. of the tablet may decrease. That is, the volume ratio of the tablet is uniform, and the hardness and abrasion of the tablet can be improved.

本發明的片劑的體積率的均勻性例如可採用以下方法指定。即,在將片劑的扁平方向長度分割成3等分的各分割體中,用X射線CT顯微鏡對位於扁平方向長度的中央且位於從上面觀察的片劑中心的邊長2mm立方體的體積率進行解析時,如果3 個分割體的立方體的體積率的相對標準偏差為5%以下,則可判定片劑的均勻性較好。 The uniformity of the volume ratio of the tablet of the present invention can be specified by the following method, for example. That is, in each divided body that divides the length of the tablet in the flat direction into 3 equal parts, the volume ratio of a cube with a side length of 2 mm at the center of the length in the flat direction and at the center of the tablet viewed from above is measured with an X-ray CT microscope When parsing, if 3 If the relative standard deviation of the volume ratio of the cube of each divided body is 5% or less, it can be judged that the uniformity of the tablet is good.

如圖1所示,片劑除了圓球狀的丸劑外,具有扁平形狀。圖1(A)示出從上面觀察的扁平片劑,而圖1(B)示出從側面觀察的扁平片劑。從上面觀察片劑時,片劑多數呈圖1(A)所示的圓形、或者橢圓形、四邊形、或長方形等形狀,但片劑通常具有對稱形態,如圖1(A)的正方形虛線所示,可指定「從上面觀察的片劑中心的立方體」。此外,從側面觀察扁平片劑時,如圖1(B)所示,可將扁平方向長度分成3等分,形成分割體,在各分割體中,如虛線所示,可指定「位於扁平方向長度的中央的立方體」。因此,可指定「位於扁平方向長度的中央且位於從上面觀察的片劑中心的邊長2mm的3個立方體」。另外,片劑為圓球狀的丸劑時,可將扁平方向設為任意方向,來指定「扁平方向長度的中央」及「從上面觀察的片劑中心」等。 As shown in Figure 1, the tablet has a flat shape in addition to the spherical pill. Fig. 1(A) shows the flat tablet viewed from above, and Fig. 1(B) shows the flat tablet viewed from the side. When viewing the tablet from above, most of the tablets are round, oval, quadrilateral, or rectangular as shown in Figure 1(A), but the tablets usually have a symmetrical shape, such as the square dotted line in Figure 1(A) As shown, "the cube in the center of the tablet viewed from above" can be specified. In addition, when viewing a flat tablet from the side, as shown in Figure 1(B), the length in the flat direction can be divided into three equal parts to form divided bodies. In each divided body, as shown by the dotted line, you can specify The length of the central cube". Therefore, it is possible to specify "3 cubes with a side length of 2 mm located at the center of the length in the flat direction and at the center of the tablet viewed from above". In addition, when the tablet is a spherical pill, the flatness direction can be set to any direction, and the "center of the length in the flatness direction" and "the center of the tablet viewed from above" can be designated.

可使用X射線CT顯微鏡對所述3個立方體進行解析,計算各立方體的體積率。而且,計算得到的3個立方體的體積率的相對標準偏差,如果相對標準偏差為5%以下,則判定片劑的均勻性較好。 The three cubes can be analyzed using an X-ray CT microscope to calculate the volume ratio of each cube. Moreover, if the calculated relative standard deviation of the volume ratio of the three cubes is less than 5%, it is determined that the uniformity of the tablet is good.

另外,片劑的扁平方向長度不足6mm時,邊長2mm的3個立方體可能部分重疊。然而,3個立方體重疊時,仍然可計算3個分割體的立方體的體積率的相對標準偏差,如果該相對標準偏差為5%以下,則可判定片劑的均勻性較好。 In addition, when the length of the tablet in the flat direction is less than 6 mm, the three cubes with a side length of 2 mm may partially overlap. However, when three cubes overlap, the relative standard deviation of the volume ratio of the three divided cubes can still be calculated. If the relative standard deviation is 5% or less, it can be determined that the uniformity of the tablet is good.

所述體積率的相對標準偏差優選為4.7%以下,進一步優選為4.5%以下。相對標準偏差越小,均勻性越好,可改善片劑的硬度或磨損度等。因此,所述體積率的相對標準偏差的下限最優選為0%以上,實際使用中可以為0.1%以上,還可以為0.3%以上,亦可以為0.4%以上。所述體積率的相對標準偏差的範圍例如可以為0.1至5%,還可以為0.3至4.7%,亦可以為0.4至4.5%。 The relative standard deviation of the volume ratio is preferably 4.7% or less, and more preferably 4.5% or less. The smaller the relative standard deviation, the better the uniformity, which can improve the hardness or abrasion of the tablet. Therefore, the lower limit of the relative standard deviation of the volume ratio is most preferably 0% or more, and in actual use, it can be 0.1% or more, 0.3% or more, or 0.4% or more. The range of the relative standard deviation of the volume ratio may be, for example, 0.1 to 5%, 0.3 to 4.7%, or 0.4 to 4.5%.

《添加劑的局部分佈的均勻性》 "The uniformity of local distribution of additives"

本發明的片劑之片劑內的添加劑的分佈均勻,即與過去的含球狀活性炭的片劑相比,本發明的片劑中添加劑的體積率的均勻性優異。例如,如圖2(B)所示,在用過去的捏合法得到的含球狀活性炭的片劑中,添加劑偏於靠近片劑上部表面的部分(用白色表示添加劑),添加劑的均勻性較差。添加劑偏於某處時,片劑的硬度或磨損度等可能降低。換言之,如果在片劑內添加劑的體積率存在不均勻,則片劑的硬度或磨損度等可能降低。即,添加劑的體積率均勻,可提高片劑的硬度及磨損度等。 In the tablet of the present invention, the distribution of additives in the tablet is uniform, that is, compared with the conventional spherical activated carbon-containing tablets, the uniformity of the volume ratio of the additives in the tablet of the present invention is excellent. For example, as shown in Figure 2(B), in the tablet containing spherical activated carbon obtained by the kneading method in the past, the additives are located near the upper surface of the tablet (the additives are shown in white), and the uniformity of the additives is poor. . When the additives are in a certain place, the hardness or abrasion of the tablet may decrease. In other words, if the volume ratio of the additive in the tablet is not uniform, the hardness or abrasion of the tablet may decrease. That is, the volume ratio of the additive is uniform, and the hardness and abrasion of the tablet can be improved.

本發明的添加劑的體積率的均勻性例如可採用以下方法指定。用X射線CT顯微鏡對從上面觀察片劑時的中心部、以及位於從中心向四方延伸的直線端部的從上面到下面的邊長1mm的5個棱柱的添加劑的體積率從上面到下面進行解析時,如果5個棱柱的每1mm3的添加劑體積率的最大值及最小值的比值為100以下,則可判定添加劑的分佈的均勻性較好。即,本發明的片劑中, 5個棱柱的添加劑體積率的最大值及最小值的比值為100以下。另一方面,過去的片劑中,5個棱柱的添加劑體積率的最大值及最小值的比值超過100,因此片劑的硬度或磨損度等降低。 The uniformity of the volume ratio of the additive of the present invention can be specified by the following method, for example. Using an X-ray CT microscope to observe the center of the tablet from the top, and the volume ratio of the additive of 5 prisms with a side length of 1 mm from top to bottom at the straight end extending from the center to the square, from top to bottom. In the analysis, if the ratio of the maximum value and the minimum value of the additive volume ratio per 1 mm 3 of the five prisms is 100 or less, it can be determined that the uniformity of the additive distribution is good. That is, in the tablet of the present invention, the ratio of the maximum value and the minimum value of the additive volume ratio of the five prisms is 100 or less. On the other hand, in a conventional tablet, the ratio of the maximum value and the minimum value of the additive volume ratio of the five prisms exceeds 100, so the hardness, abrasion, etc. of the tablet are reduced.

如圖3所示,片劑除了圓球狀的丸劑外,具有扁平形狀。圖3(A)示出從上面觀察的扁平片劑,而圖3(B)示出從側面觀察的扁平片劑。從上面觀察片劑時,片劑多數呈圖3(A)的圓形、或者橢圓形、四邊形、或長方形等形狀,但片劑通常具有對稱形態,如圖3(A)的C正方形虛線所示,可指定「從上面觀察時的中心部的棱柱」。此外,可指定圖3(A)的N、E、S、以及W正方形虛線所示的「位於從中心向四方延伸的直線端部的棱柱」。此外,從側面觀察扁平片劑時,如圖3(B)的虛線所示,所述棱柱位於片劑的扁平方向的上面到下面。因此,可指定「從上面觀察時的中心部的棱柱」及「位於從片劑中心向四方延伸的直線端部的棱柱」。 As shown in Fig. 3, the tablet has a flat shape except for the spherical pill. Fig. 3(A) shows the flat tablet viewed from above, and Fig. 3(B) shows the flat tablet viewed from the side. When viewing the tablet from above, most of the tablets are round, oval, quadrilateral, or rectangular as shown in Figure 3(A), but the tablets usually have a symmetrical shape, as shown by the dotted line of C square in Figure 3(A) You can specify "Prism at the center when viewed from above". In addition, it is possible to specify the "prism at the end of a straight line extending from the center to the four directions" shown by the dotted lines in the squares of N, E, S, and W in FIG. 3(A). In addition, when the flat tablet is viewed from the side, as shown by the broken line in FIG. 3(B), the prisms are located from the upper surface to the lower surface of the tablet in the flat direction. Therefore, it is possible to specify "the prism at the center when viewed from above" and "the prism at the end of a straight line extending from the center of the tablet in all directions".

可使用X射線CT顯微鏡對所述5個棱柱從上面到下面進行解析,計算各棱柱的添加劑的體積率。而且,可在棱柱的任意位置計算每1mm3的添加劑體積率,求出每1mm3的添加劑體積率的最大值及最小值。 An X-ray CT microscope can be used to analyze the five prisms from top to bottom, and calculate the volume ratio of the additives of each prism. Furthermore, the additive volume ratio per 1 mm 3 can be calculated at any position of the prism, and the maximum and minimum additive volume ratios per 1 mm 3 can be obtained.

本發明中,如果每1mm3的添加劑體積率的最大值及最小值的比值為100以下,則可判定添加劑的分佈的均勻性較好,所述最大值及最小值的比值優選為99以下,更優選為98以下,進一步優選為96以下。最大值及最小值的比值越小,添加劑的均勻性越好,可改善片劑的硬度或磨損度等。因此,最大值及最小值的比值的下 限最優選為1以上,實際使用中可以為2以上,還可以為4以上,亦可以為6以上。最大值及最小值的比值的範圍例如可以為1至100,還可以為2至99,還可以為4至98,亦可以為6至96。 In the present invention, if the ratio of the maximum value and the minimum value of the additive volume ratio per 1 mm 3 is 100 or less, it can be determined that the uniformity of the additive distribution is good, and the ratio of the maximum value and the minimum value is preferably 99 or less. It is more preferably 98 or less, and even more preferably 96 or less. The smaller the ratio between the maximum value and the minimum value, the better the uniformity of the additive, which can improve the hardness or abrasion of the tablet. Therefore, the lower limit of the ratio of the maximum value to the minimum value is most preferably 1 or more, and in actual use, it may be 2 or more, 4 or more, or 6 or more. The range of the ratio of the maximum value to the minimum value may be, for example, 1 to 100, 2 to 99, 4 to 98, or 6 to 96.

另外,根據片劑的形狀,與C位置的棱柱相比,N、E、S、以及W位置的棱柱高度可能較低,但此時通過求出能夠測定每1mm3的添加劑體積率的從上面到下面的添加劑體積率,可計算「添加劑體積率的最大值及最小值的比值」。 In addition, depending on the shape of the tablet, the height of the prisms at the positions N, E, S, and W may be lower than the prisms at the C position, but in this case, the volume ratio of the additive per 1 mm 3 can be measured from the top To the following additive volume rate, the "ratio of the maximum and minimum additive volume rate" can be calculated.

(X射線CT顯微鏡) (X-ray CT microscope)

本發明的對片劑的體積率及添加劑的體積率進行解析的X射線CT顯微鏡是能夠以亞微米級的高解析度對材料、或片劑等試料的內部進行平面(2D)、或立體(3D)觀察的裝置。能夠以高解析度對材料、或片劑等的微細結構進行解析。例如,如本實施例中記載所示,能夠對由球狀活性炭及添加劑構成的片劑的體積率進行解析,或者僅對添加劑的體積率進行解析。 The X-ray CT microscope for analyzing the volume ratio of tablets and the volume ratio of additives of the present invention is capable of performing planar (2D) or three-dimensional (2D) or three-dimensional ( 3D) Observation device. It is possible to analyze the fine structure of materials or tablets with high resolution. For example, as described in this example, it is possible to analyze the volume rate of a tablet composed of spherical activated carbon and additives, or analyze only the volume rate of additives.

作為X射線CT顯微鏡,可使用市售的「nano3DX(高解析3DX射線顯微鏡:理學株式會社」及「三維測量X射線CT裝置TDM系列:大和科學株式會社」。所述裝置具有1μm以下的高解析度,可使用裝置附帶的軟體、或圖像處理軟體ImageJ等,計算片劑的體積率、或添加劑體積率。 As the X-ray CT microscope, commercially available "nano3DX (high resolution 3DX ray microscope: Rigaku Co., Ltd." and "three-dimensional measurement X-ray CT device TDM series: Yamato Scientific Co., Ltd." can be used. The device has a high resolution of 1 μm or less Degree, you can use the software attached to the device, or image processing software ImageJ, etc., to calculate the volume rate of the tablet or the volume rate of the additive.

(黏合用添加劑) (Adhesive additives)

本發明的片劑中所使用的黏合用添加劑含有:藻酸鈉、藻酸丙二醇酯、羧甲基纖維素、羧甲基纖維素鈣、茄替膠、角叉菜膠、羧基乙烯聚合物、羧甲基纖維素鈉、黃原膠、瓜爾豆膠、榅桲籽膠、葡甘露聚糖、共聚維酮、結蘭膠、明膠、羅望子膠、他拉膠、葡聚糖、玉米澱粉、黃蓍膠、透明質酸鈉、羥乙基纖維素、羥丙澱粉、羥丙基纖維素、羥丙甲纖維素、普魯蘭多糖、聚維酮、聚環氧乙烷、聚乙烯醇、聚乙烯醇-丙烯酸-甲基丙烯酸甲酯共聚物、聚乙烯二醇6000、乙基纖維素、甲基纖維素、磷酸交聯澱粉、刺槐豆膠、瓊脂、寒梅粉、完全預膠化澱粉、結晶纖維素甲基纖維素鈉、氧化澱粉、低取代度羥丙基纖維素、部分預膠化澱粉、糖類、乙基糖醇類、或其組合。口服給藥用球狀吸附炭上覆蓋有黏合用添加劑且該黏合用添加劑使各口服給藥用球狀吸附炭結合的本發明的片劑具有105N以上的硬度。 The adhesive additive used in the tablet of the present invention contains: sodium alginate, propylene glycol alginate, carboxymethyl cellulose, calcium carboxymethyl cellulose, gum ghatti, carrageenan, carboxyvinyl polymer, Sodium carboxymethyl cellulose, xanthan gum, guar gum, quince seed gum, glucomannan, copovidone, gellan gum, gelatin, tamarind gum, tara gum, dextran, corn starch , Tragacanth, sodium hyaluronate, hydroxyethyl cellulose, hydroxypropyl starch, hydroxypropyl cellulose, hypromellose, pullulan, povidone, polyethylene oxide, polyvinyl alcohol , Polyvinyl alcohol-acrylic acid-methyl methacrylate copolymer, polyethylene glycol 6000, ethyl cellulose, methyl cellulose, phosphoric acid cross-linked starch, locust bean gum, agar, winter plum powder, fully pregelatinized starch , Crystalline cellulose sodium methylcellulose, oxidized starch, low-substituted hydroxypropyl cellulose, partially pregelatinized starch, sugars, ethyl sugar alcohols, or combinations thereof. The spherical adsorbent carbon for oral administration is covered with an adhesive additive, and the adhesive additive allows the tablet of the present invention in which each spherical adsorbent carbon for oral administration is bonded to have a hardness of 105 N or more.

(其他添加劑) (Other additives)

以下對可作為黏合用添加劑以外的添加劑(其他添加劑)使用的添加劑進行說明。 The additives that can be used as additives (other additives) other than the adhesive additives will be described below.

通常用於醫藥品的添加劑記載在「醫藥品添加物事典2016」中,例如可列舉出賦形劑、潤滑劑、崩散劑、表面活性劑、以及結合劑等。賦形劑、潤滑劑、崩散劑、以及結合劑的功能未必單一,例如分類為賦形劑的結晶纖維素在多數情況下還具有作為崩散劑的功能,此外在直接打片法中還具有作為提高成型性的結合劑的功 能。因此,賦形劑、潤滑劑、崩散劑、以及結合劑各自的功能可能重複。下述列舉出賦形劑、潤滑劑、崩散劑、以及結合劑的示例,但作為其他添加劑可以使用未分類為這些添加劑的添加劑。 Additives commonly used in pharmaceuticals are described in "Drug Additives Reference 2016", and examples include excipients, lubricants, disintegrating agents, surfactants, and binding agents. The functions of excipients, lubricants, disintegrating agents, and binding agents are not necessarily single. For example, crystalline cellulose classified as excipients also functions as a disintegrating agent in most cases. In addition, it also functions as a disintegrant in direct tableting. The function of the binder to improve the formability can. Therefore, the functions of excipients, lubricants, disintegrating agents, and binders may be repeated. Examples of excipients, lubricants, disintegrating agents, and binders are listed below, but additives that are not classified as these additives can be used as other additives.

賦形劑是主要用於增量(增量劑)或稀釋(稀釋劑)的添加劑,具體而言可列舉出澱粉、磷酸氫鈣、合成矽酸鋁、或三矽酸鎂等。 Excipients are additives mainly used for augmentation (extender) or dilution (diluent), and specifically include starch, dibasic calcium phosphate, synthetic aluminum silicate, or magnesium trisilicate.

此外,結合劑是用於對主藥、增量劑賦予結合力並進行成型的添加劑,可用於維持劑型,防止包裝製程、運輸時的破損,並提高機械強度。具體而言,可列舉出結晶纖維素、低取代度羥丙基纖維素、羧甲基纖維素鈉、粉末纖維素、羥丙甲纖維素、甲基纖維素、羥丙基纖維素、澱粉、完全預膠化澱粉、部分預膠化澱粉、葡聚糖、阿拉伯膠、藻酸鈉、黃蓍膠、精製明膠、聚乙烯醇、或聚維酮等。 In addition, the binding agent is an additive used to impart binding force to the main drug and extender and to form it. It can be used to maintain the dosage form, prevent damage during packaging and transportation, and improve mechanical strength. Specifically, crystalline cellulose, low-substituted hydroxypropyl cellulose, sodium carboxymethyl cellulose, powdered cellulose, hypromellose, methyl cellulose, hydroxypropyl cellulose, starch, Fully pregelatinized starch, partially pregelatinized starch, dextran, acacia, sodium alginate, tragacanth, refined gelatin, polyvinyl alcohol, or povidone, etc.

進而,崩散劑是服用片劑時用於在消化道內浸潤,使製劑崩散並分散為微粒的添加劑。具體而言,可列舉出羧甲基纖維素、羧甲基纖維素鈣、低取代度羥丙基纖維素、羥丙甲纖維素、粉末纖維素、澱粉、羧甲基澱粉鈉、或羥丙基澱粉等。 Furthermore, the disintegrating powder is an additive used to infiltrate the digestive tract when taking a tablet to disintegrate and disperse the preparation into fine particles. Specifically, carboxymethyl cellulose, calcium carboxymethyl cellulose, low-substituted hydroxypropyl cellulose, hypromellose, powdered cellulose, starch, sodium carboxymethyl starch, or hydroxypropyl Base starch, etc.

潤滑劑是在打片中具有對粉體流動性、填充性、附著性、以及成型性等諸性質進行改善的功能的添加劑,可用於提高片劑品質和製造效率。具體而言,可列舉出蔗糖脂肪酸酯、滑石、硬脂酸鎂、或硬脂酸等。 Lubricants are additives that have the function of improving powder fluidity, filling, adhesion, and moldability during tableting, and can be used to improve tablet quality and manufacturing efficiency. Specifically, sucrose fatty acid ester, talc, magnesium stearate, stearic acid, etc. can be mentioned.

表面活性劑可列舉出烷基芳基聚醚醇、高級醇硫酸化物、N-椰油醯-L-精氨酸乙酯DL-吡咯烷酮羧酸鹽、N-椰油醯-N-甲膠基乙磺酸鈉、膽固醇、自乳化型甘油單硬脂酸酯、蔗糖脂肪酸酯、角鯊烷、硬脂醇、聚乙二醇40硬脂酸酯、鯨蠟醇、聚西托醇1000、皮脂酸二乙酯、失水山梨醇脂肪酸酯、失水山梨醇倍半油酸酯、十二烷基苯磺酸鈉、失水山梨醇三油酸酯、壬基苯氧基聚氧乙烯乙烷硫酸酯銨液、聚氧乙烯辛基苯基醚、聚氧乙烯油胺、聚氧乙烯硬化蓖麻油20、聚氧乙烯硬化蓖麻油60、聚氧乙烯硬脂醇醚、聚氧乙烯鯨蠟醇醚、聚氧乙烯失水山梨醇單月桂酸酯、聚氧乙烯山梨醇蜂蠟、聚氧乙烯壬基苯基醚、聚氧乙烯(20)聚氧丙烯(20)二醇、聚氧乙烯(105)聚氧丙烯(5)二醇、聚氧乙烯(120)聚氧丙烯(40)二醇、聚氧乙烯(124)聚氧丙烯(39)二醇、聚氧乙烯(160)聚氧丙烯(30)二醇、聚氧乙烯(10)聚氧丙烯(4)鯨蠟醇醚、聚氧乙烯(2 E.O.)月桂醇醚硫酸鈉(70%)、聚乙二醇35蓖麻油、聚山梨酯20、聚山梨酯60、聚山梨酯80、聚乙二醇400、失水山梨醇單油酸酯、甘油單硬脂酸酯、失水山梨醇單硬脂酸酯、失水山梨醇單月桂酸酯、N-椰子油脂肪酸醯基L-精氨酸乙酯-DL-吡咯烷酮羧酸鹽、月桂基二甲基氧化胺液、月桂基吡咯烷酮、月桂基硫酸鈉、月桂酸二乙醇醯膠、月桂醯肌氨酸鈉、聚桂醇、月桂醇聚氧乙烯醚磷酸鈉或油醇聚氧乙烯醚磷酸酯(8MOL)等。 Surfactants include alkyl aryl polyether alcohols, higher alcohol sulfates, N-coconut oil-L-arginine ethyl ester DL-pyrrolidone carboxylate, N-coco oil-N-methyl gum base Sodium ethanesulfonate, cholesterol, self-emulsifying glycerol monostearate, sucrose fatty acid ester, squalane, stearyl alcohol, polyethylene glycol 40 stearate, cetyl alcohol, cetrol 1000, Diethyl sebate, sorbitan fatty acid ester, sorbitan sesquioleate, sodium dodecylbenzene sulfonate, sorbitan trioleate, nonylphenoxy polyoxyethylene Ethane sulfate ammonium liquid, polyoxyethylene octyl phenyl ether, polyoxyethylene oleylamine, polyoxyethylene hardened castor oil 20, polyoxyethylene hardened castor oil 60, polyoxyethylene stearyl alcohol ether, polyoxyethylene whale Wax alcohol ether, polyoxyethylene sorbitan monolaurate, polyoxyethylene sorbitol beeswax, polyoxyethylene nonylphenyl ether, polyoxyethylene (20) polyoxypropylene (20) glycol, polyoxyethylene (105) Polyoxypropylene (5) glycol, polyoxyethylene (120) polyoxypropylene (40) glycol, polyoxyethylene (124) polyoxypropylene (39) glycol, polyoxyethylene (160) polyoxy Propylene (30) glycol, polyoxyethylene (10) polyoxypropylene (4) cetyl alcohol ether, polyoxyethylene (2 EO) sodium laureth ether sulfate (70%), polyethylene glycol 35 castor oil, poly Sorbate 20, Polysorbate 60, Polysorbate 80, Polyethylene Glycol 400, Sorbitan Monooleate, Glycerol Monostearate, Sorbitan Monostearate, Sorbitan Monolaurate, N-coconut oil fatty acid ester L-arginine ethyl ester-DL-pyrrolidone carboxylate, lauryl dimethyl amine oxide liquid, lauryl pyrrolidone, sodium lauryl sulfate, lauric acid diethanolic acid Gum, sodium lauryl sarcosinate, lauryl alcohol, sodium laureth phosphate or oleyl alcohol polyoxyethylene ether phosphate (8MOL), etc.

(黏合用添加劑的含量) (Content of bonding additives)

口服給藥用球狀吸附炭(例如,球狀活性炭)與黏合用添加劑的重量比只要可獲得本發明的效果,則並無特別限定,但本發明的片劑的黏合用添加劑的含量優選為1重量%以上,更優選為1.5重量%以上,進一步優選為2重量%以上。黏合用添加劑的量過少時,獲得的片劑的硬度可能降低。黏合用添加劑的上限並無限定,但黏合用添加劑優選為35重量%以下,更優選為30重量%以下,進一步優選為25重量%以下。如果黏合用添加劑過多,則可能片劑體積較大,片劑服用量較多。從獲得的片劑的硬度容易為105N以上的方面出發,本發明的片劑的黏合用添加劑的含量範圍優選為1至35重量%(或者,1至30重量%或1至25重量%亦可),更優選為1.5至30重量%(或者,1.5至25重量%或1.5至20重量%亦可),進而更優選為2至25重量%(或者,2至20重量%或2至17重量%亦可)。 The weight ratio of spherical adsorbent carbon (for example, spherical activated carbon) for oral administration to the adhesive additive is not particularly limited as long as the effect of the present invention can be obtained, but the content of the adhesive additive of the tablet of the present invention is preferably 1% by weight or more, more preferably 1.5% by weight or more, and even more preferably 2% by weight or more. When the amount of the bonding additive is too small, the hardness of the obtained tablet may decrease. The upper limit of the adhesive additive is not limited, but the adhesive additive is preferably 35% by weight or less, more preferably 30% by weight or less, and still more preferably 25% by weight or less. If there are too many additives for bonding, the volume of the tablet may be larger and the dosage of the tablet may be larger. From the viewpoint that the hardness of the obtained tablet is easily 105N or more, the content of the adhesive additive of the tablet of the present invention is preferably 1 to 35% by weight (or 1 to 30% by weight or 1 to 25% by weight) ), more preferably 1.5 to 30% by weight (alternatively, 1.5 to 25% by weight or 1.5 to 20% by weight), and even more preferably 2 to 25% by weight (or, 2 to 20% by weight or 2 to 17% by weight) % Can also).

此外,本發明的片劑作為添加劑可以含有其他添加劑,黏合用添加劑與其他添加劑的重量比只要可獲得本發明的效果,則並無特別限定,但優選為相對於黏合用添加劑100重量份,其他添加劑優選為10000重量份以下,更優選為1000重量份以下,進一步優選為100重量份以下,最優選為50重量份以下。如果其他添加劑的量過多,則獲得的片劑的硬度可能降低。另外,上述重量比的下限並無特別限定,相對於黏合用添加劑100重量份,其他添加劑的含量例如可以為0.1重量份以上,還可以為1重量份以上,亦可以為10重量份以上。 In addition, the tablet of the present invention may contain other additives as an additive. The weight ratio of the adhesive additive to other additives is not particularly limited as long as the effects of the present invention can be obtained, but it is preferably relative to 100 parts by weight of the adhesive additive. The additive is preferably 10000 parts by weight or less, more preferably 1000 parts by weight or less, still more preferably 100 parts by weight or less, and most preferably 50 parts by weight or less. If the amount of other additives is too much, the hardness of the obtained tablet may decrease. In addition, the lower limit of the above-mentioned weight ratio is not particularly limited, and the content of other additives relative to 100 parts by weight of the adhesive additive may be, for example, 0.1 parts by weight or more, 1 part by weight or more, or 10 parts by weight or more.

〔2〕片劑的製造方法 〔2〕Method for manufacturing tablets

本發明的片劑的製造方法包含以下製程:(1)將包含選自由藻酸鈉、藻酸丙二醇酯、羧甲基纖維素、羧甲基纖維素鈣、茄替膠、角叉菜膠、羧基乙烯聚合物、羧甲基纖維素鈉、黃原膠、瓜爾豆膠、榅桲籽膠、葡甘露聚糖、共聚維酮、結蘭膠、明膠、羅望子膠、他拉膠、葡聚糖、玉米澱粉、黃蓍膠、透明質酸鈉、羥乙基纖維素、羥丙澱粉、羥丙基纖維素、羥丙甲纖維素、普魯蘭多糖、聚維酮、聚環氧乙烷、聚乙烯醇、聚乙烯醇-丙烯酸-甲基丙烯酸甲酯共聚物、聚乙烯二醇6000、乙基纖維素、甲基纖維素、磷酸交聯澱粉、刺槐豆膠、瓊脂、寒梅粉、完全預膠化澱粉、結晶纖維素甲基纖維素鈉、氧化澱粉、低取代度羥丙基纖維素、部分預膠化澱粉、糖類、以及糖醇類所組成的組中的黏合用添加劑的溶液噴到或滴到口服給藥用球狀吸附炭(例如,球狀活性炭)上,用黏合用添加劑覆蓋口服給藥用球狀吸附炭的製程;(2)向被覆蓋的所述口服給藥用球狀吸附炭添加溶媒,然後通過壓縮成型,獲得成型體的壓縮成型製程;以及(3)對獲得的成型體進行乾燥的製程。 The manufacturing method of the tablet of the present invention includes the following manufacturing process: (1) It contains selected from sodium alginate, propylene glycol alginate, carboxymethyl cellulose, calcium carboxymethyl cellulose, gum ghatti, carrageenan, Carboxy vinyl polymer, sodium carboxymethyl cellulose, xanthan gum, guar gum, quince seed gum, glucomannan, copovidone, gellan gum, gelatin, tamarind gum, tara gum, grape Glycan, corn starch, tragacanth, sodium hyaluronate, hydroxyethyl cellulose, hydroxypropyl starch, hydroxypropyl cellulose, hypromellose, pullulan, povidone, polyethylene oxide Alkyl, polyvinyl alcohol, polyvinyl alcohol-acrylic acid-methyl methacrylate copolymer, polyethylene glycol 6000, ethyl cellulose, methyl cellulose, phosphoric acid cross-linked starch, locust bean gum, agar, winter plum powder, Adhesive additives in the group consisting of fully pregelatinized starch, crystalline cellulose methylcellulose sodium, oxidized starch, low-substituted hydroxypropyl cellulose, partially pregelatinized starch, sugars, and sugar alcohols Spray or drop onto the spherical adsorbent carbon for oral administration (for example, spherical activated carbon), and cover the manufacturing process of the spherical adsorbent carbon for oral administration with adhesive additives; (2) To the covered oral administration The spherical adsorption carbon is used to add a solvent, and then compression molding is performed to obtain a compression molding process of the molded body; and (3) a process of drying the obtained molded body.

本發明的片劑的製造方法中使用的「黏合用添加劑」可使用所述「〔1〕含口服給藥用球狀吸附炭的片劑」項中記載的黏合用添加劑。 As the "adhesive additive" used in the method of manufacturing the tablet of the present invention, the adhesive additive described in the section "[1] Tablets containing spherical adsorption carbon for oral administration" can be used.

《覆蓋製程(1)》 "Covering Process (1)"

覆蓋方法(1)將包含選自由藻酸鈉、藻酸丙二醇酯、羧甲基纖維素、羧甲基纖維素鈣、茄替膠、角叉菜膠、羧基乙烯聚合物、羧甲基纖維素鈉、黃原膠、瓜爾豆膠、榅桲籽膠、葡甘露聚糖、共聚維酮、結蘭膠、明膠、羅望子膠、他拉膠、葡聚糖、玉米澱粉、黃蓍膠、透明質酸鈉、羥乙基纖維素、羥丙澱粉、羥丙基纖維素、羥丙甲纖維素、普魯蘭多糖、聚維酮、聚環氧乙烷、聚乙烯醇、聚乙烯醇-丙烯酸-甲基丙烯酸甲酯共聚物、聚乙烯二醇6000、乙基纖維素、甲基纖維素、磷酸交聯澱粉、刺槐豆膠、瓊脂、寒梅粉、完全預膠化澱粉、結晶纖維素甲基纖維素鈉、氧化澱粉、低取代度羥丙基纖維素、部分預膠化澱粉、糖類、以及糖醇類所組成的組中的黏合用添加劑的溶液噴到口服給藥用球狀吸附炭(例如,球狀活性炭)上,用黏合用添加劑覆蓋口服給藥用球狀吸附炭。作為覆蓋方法,使用噴霧法。作為噴霧法,可列舉出頂噴方式、切線噴方式、底噴方式或側噴方式等。 Covering method (1) will contain selected from sodium alginate, propylene glycol alginate, carboxymethyl cellulose, calcium carboxymethyl cellulose, gum ghatti, carrageenan, carboxyvinyl polymer, carboxymethyl cellulose Sodium, xanthan gum, guar gum, quince seed gum, glucomannan, copovidone, gellan gum, gelatin, tamarind gum, tara gum, dextran, corn starch, tragacanth, Sodium hyaluronate, hydroxyethyl cellulose, hydroxypropyl starch, hydroxypropyl cellulose, hypromellose, pullulan, povidone, polyethylene oxide, polyvinyl alcohol, polyvinyl alcohol- Acrylic acid-methyl methacrylate copolymer, polyethylene glycol 6000, ethyl cellulose, methyl cellulose, phosphoric acid cross-linked starch, locust bean gum, agar, winter plum powder, fully pregelatinized starch, crystalline cellulose The solution of adhesive additives in the group consisting of sodium base cellulose, oxidized starch, low degree of substitution hydroxypropyl cellulose, partially pregelatinized starch, sugars, and sugar alcohols is sprayed onto spherical adsorption charcoal for oral administration (For example, spherical activated carbon), the spherical adsorbent carbon for oral administration is covered with adhesive additives. As the covering method, a spray method is used. Examples of the spray method include a top spray method, a tangential spray method, a bottom spray method, or a side spray method.

例如採用頂噴方式時,將黏合用添加劑及其他添加劑溶解到溶媒中,調製出噴液。然後例如將口服給藥用球狀吸附炭投入轉動流動鍍膜裝置或流動層造粒裝置,從上部噴出噴液霧。 For example, when using the top spray method, the adhesive additives and other additives are dissolved in the solvent to prepare the spray liquid. Then, for example, the spherical adsorbent carbon for oral administration is put into a rotary flow coating device or a fluidized bed granulation device, and spray liquid mist is sprayed from the upper part.

作為用於噴液的溶媒,並無特別限定,能夠使用可作為醫藥品添加物使用的所有有機溶媒,例如,可列舉出水、乙酸、丙酮、苯甲醚、1-丁醇、2-丁醇、乙酸正丁酯、叔丁基甲基醚、異丙苯、二甲基亞碸、乙醇、乙酸乙酯、二乙醚、甲酸乙酯、甲酸、庚烷、乙酸異丁酯、乙酸異丙酯、乙酸甲酯、3-甲基-1-丁醇、甲基乙基酮、 2-甲基-1-丙醇、戊烷、1-戊醇、1-丙醇、2-丙醇、乙酸丙酯、四氫呋喃、乙腈、氯苯、氯仿、環己烷、1,2-二氯乙烯、二氯甲烷、N,N-二甲基乙醯胺、N,N-二甲基甲醯胺、1,4-二氧六環、2-乙氧基乙醇、乙二醇、甲醯胺、己烷、甲醇、2-甲氧基乙醇、甲基丁基甲酮、甲基環己烷、N-甲基吡咯烷酮、硝基甲烷、吡啶、環丁碸、四氫化萘、甲苯、1,1,2-三氯乙烯或二甲苯等。此外,表面活性劑並無特別限定,可列舉出烷基芳基聚醚醇、高級醇硫酸化物、N-椰油醯-L-精氨酸乙酯DL-吡咯烷酮羧酸鹽、N-椰油醯-N-甲胺基乙磺酸鈉、膽固醇、自乳化型甘油單硬脂酸酯、蔗糖脂肪酸酯、角鯊烷、硬脂醇、聚乙二醇40硬脂酸酯、鯨蠟醇、聚西托醇1000、皮脂酸二乙酯、失水山梨醇脂肪酸酯、失水山梨醇倍半油酸酯、十二烷基苯磺酸鈉、失水山梨醇三油酸酯、壬基苯氧基聚氧乙烯乙烷硫酸酯銨液、聚氧乙烯辛基苯基醚、聚氧乙烯油胺、聚氧乙烯硬化蓖麻油20、聚氧乙烯硬化蓖麻油60、聚氧乙烯硬脂醇醚、聚氧乙烯鯨蠟醇醚、聚氧乙烯失水山梨醇單月桂酸酯、聚氧乙烯山梨醇蜂蠟、聚氧乙烯壬基苯基醚、聚氧乙烯(20)聚氧丙烯(20)二醇、聚氧乙烯(105)聚氧丙烯(5)二醇、聚氧乙烯(120)聚氧丙烯(40)二醇、聚氧乙烯(124)聚氧丙烯(39)二醇、聚氧乙烯(160)聚氧丙烯(30)二醇、聚氧乙烯(10)聚氧丙烯(4)鯨蠟醇醚、聚氧乙烯(2 E.O.)月桂醇醚硫酸鈉(70%)、聚乙二醇35蓖麻油、聚山梨酯20、聚山梨酯60、聚山梨酯80、聚乙二醇400、失水山梨醇單油酸酯、甘油單硬脂酸酯、失水山梨醇單硬脂酸酯、失水山梨醇單月桂酸酯、N-椰子油脂肪酸醯 基L-精氨酸乙酯.DL-吡咯烷酮羧酸鹽、月桂基二甲基氧化胺液、月桂基吡咯烷酮、月桂基硫酸鈉、月桂酸二乙醇醯胺、月桂醯肌氨酸鈉、聚桂醇、月桂醇聚氧乙烯醚磷酸鈉或油醇聚氧乙烯醚磷酸酯(8MOL)等。 The solvent used for spraying is not particularly limited. All organic solvents that can be used as pharmaceutical additives can be used. For example, water, acetic acid, acetone, anisole, 1-butanol, 2-butanol can be used. , N-butyl acetate, tert-butyl methyl ether, cumene, dimethyl sulfene, ethanol, ethyl acetate, diethyl ether, ethyl formate, formic acid, heptane, isobutyl acetate, isopropyl acetate, acetic acid Methyl ester, 3-methyl-1-butanol, methyl ethyl ketone, 2-methyl-1-propanol, pentane, 1-pentanol, 1-propanol, 2-propanol, propyl acetate, tetrahydrofuran, acetonitrile, chlorobenzene, chloroform, cyclohexane, 1,2-di Vinyl chloride, dichloromethane, N,N-dimethylacetamide, N,N-dimethylformamide, 1,4-dioxane, 2-ethoxyethanol, ethylene glycol, methyl Amide, hexane, methanol, 2-methoxyethanol, methyl butyl ketone, methyl cyclohexane, N-methyl pyrrolidone, nitromethane, pyridine, cyclobutylene, tetralin, toluene, 1, 1,2-Trichloroethylene or xylene, etc. In addition, the surfactant is not particularly limited, and examples include alkyl aryl polyether alcohols, higher alcohol sulfates, N-coconut oil-L-arginine ethyl ester DL-pyrrolidone carboxylate, and N-coco oil Sodium-N-methylaminoethanesulfonate, cholesterol, self-emulsifying glycerol monostearate, sucrose fatty acid ester, squalane, stearyl alcohol, polyethylene glycol 40 stearate, cetyl alcohol , Polycetol 1000, diethyl sebanoate, sorbitan fatty acid ester, sorbitan sesquioleate, sodium dodecylbenzene sulfonate, sorbitan trioleate, nonane Base phenoxy polyoxyethylene ethane sulfate ammonium liquid, polyoxyethylene octyl phenyl ether, polyoxyethylene oleylamine, polyoxyethylene hardened castor oil 20, polyoxyethylene hardened castor oil 60, polyoxyethylene stearin Alcohol ether, polyoxyethylene cetyl alcohol ether, polyoxyethylene sorbitan monolaurate, polyoxyethylene sorbitol beeswax, polyoxyethylene nonylphenyl ether, polyoxyethylene (20) polyoxypropylene (20) ) Glycol, polyoxyethylene (105) polyoxypropylene (5) glycol, polyoxyethylene (120) polyoxypropylene (40) glycol, polyoxyethylene (124) polyoxypropylene (39) glycol, poly Ethylene oxide (160) polyoxypropylene (30) glycol, polyoxyethylene (10) polyoxypropylene (4) cetyl alcohol ether, polyoxyethylene (2 EO) sodium laureth ether sulfate (70%), polyethylene Glycol 35 castor oil, polysorbate 20, polysorbate 60, polysorbate 80, polyethylene glycol 400, sorbitan monooleate, glycerol monostearate, sorbitan monostearate Ester, sorbitan monolaurate, N-coconut oil fatty acid Base L-arginine ethyl ester. DL-pyrrolidone carboxylate, lauryl dimethyl amine oxide solution, lauryl pyrrolidone, sodium lauryl sulfate, diethanolamide laurate, sodium lauryl sarcosinate, lauryl alcohol, polyoxyethylene lauryl ether phosphate Sodium or oleyl alcohol polyoxyethylene ether phosphate (8MOL), etc.

相對於溶媒量的黏合用添加劑的量只要黏合用添加劑基本均勻覆蓋口服給藥用球狀吸附炭(例如,球狀活性炭),則並無特別限定,相對於溶媒,黏合用添加劑優選為0.01至100w/v%,更優選為0.1至50w/v%,進一步優選為1至15w/v%。 The amount of the adhesive additive relative to the amount of the solvent is not particularly limited as long as the adhesive additive substantially uniformly covers the spherical adsorbent carbon for oral administration (for example, spherical activated carbon). The amount of the adhesive additive is preferably 0.01 to 100w/v%, more preferably 0.1 to 50w/v%, still more preferably 1 to 15w/v%.

《壓縮成型製程(2)》 "Compression Molding Process (2)"

壓縮成型製程(2)向被覆蓋的所述口服給藥用球狀吸附炭(例如,球狀活性炭)添加溶媒,然後進行壓縮成型。例如,向被覆蓋的口服給藥用球狀吸附炭添加溶媒,進行壓縮成型後,可通過乾燥,獲得強度105N以上的片劑。 The compression molding process (2) adds a solvent to the covered spherical adsorption carbon (for example, spherical activated carbon) for oral administration, and then performs compression molding. For example, a solvent is added to the covered spherical adsorption carbon for oral administration, and after compression molding, a tablet with a strength of 105N or more can be obtained by drying.

作為溶媒,可列舉出有機溶媒、水、或其混合液。有機溶媒及水的混合液中的有機溶媒與水的容量比並無特別限定,優選為5:95至95:5,更優選為15:85至85:15,進一步優選為30:70至70:30。採用所述範圍,能夠使水浸透覆蓋口服給藥用球狀吸附炭的黏合用添加劑。 As the solvent, an organic solvent, water, or a mixture thereof can be mentioned. The volume ratio of the organic solvent to the water in the mixed liquid of the organic solvent and water is not particularly limited, but is preferably 5:95 to 95:5, more preferably 15:85 to 85:15, and still more preferably 30:70 to 70 : 30. Within this range, the adhesive additive that covers the spherical adsorption carbon for oral administration can be saturated with water.

(有機溶媒) (Organic solvent)

可用於所述製造方法的有機溶媒只要可獲得本發明的效果,則並無特別限定,例如,可列舉出乙酸、丙酮、苯甲醚、1-丁醇、2-丁醇、乙酸正丁酯、叔丁基甲基醚、異丙苯、二甲基亞碸、乙醇、乙酸乙酯、二乙醚、甲酸乙酯、甲酸、庚烷、乙酸異丁酯、乙酸異丙酯、乙酸甲酯、3-甲基-1-丁醇、甲基乙基酮、2-甲基-1-丙醇、戊烷、1-戊醇、1-丙醇、2-丙醇、乙酸丙酯、四氫呋喃、乙腈、氯苯、氯仿、環己烷、1,2-二氯乙烯、二氯甲烷、N,N-二甲基乙醯胺、N,N-二甲基甲醯胺、1,4-二氧六環、2-乙氧基乙醇、乙二醇、甲醯胺、己烷、甲醇、2-甲氧基乙醇、甲基丁基甲酮、甲基環己烷、N-甲基吡咯烷酮、硝基甲烷、吡啶、環丁碸、四氫化萘、甲苯、1,1,2-三氯乙烯或二甲苯等。 The organic solvent that can be used in the production method is not particularly limited as long as the effects of the present invention can be obtained. For example, acetic acid, acetone, anisole, 1-butanol, 2-butanol, and n-butyl acetate can be cited. , Tert-butyl methyl ether, cumene, dimethyl sulfide, ethanol, ethyl acetate, diethyl ether, ethyl formate, formic acid, heptane, isobutyl acetate, isopropyl acetate, methyl acetate, 3- Methyl-1-butanol, methyl ethyl ketone, 2-methyl-1-propanol, pentane, 1-pentanol, 1-propanol, 2-propanol, propyl acetate, tetrahydrofuran, acetonitrile, Chlorobenzene, chloroform, cyclohexane, 1,2-dichloroethylene, methylene chloride, N,N-dimethylacetamide, N,N-dimethylformamide, 1,4-dioxane Cyclo, 2-ethoxyethanol, ethylene glycol, formamide, hexane, methanol, 2-methoxyethanol, methyl butyl ketone, methyl cyclohexane, N-methylpyrrolidone, nitromethane, Pyridine, cyclobutylene, tetralin, toluene, 1,1,2-trichloroethylene or xylene, etc.

《乾燥製程(3)》 "Drying Process (3)"

本發明的片劑的製造方法中,對獲得的成型體進行乾燥。乾燥方法只要成型體的溶媒蒸發,則並無限定,例如,可列舉出凍結乾燥、減壓乾燥、送風乾燥、自然乾燥、或加熱乾燥。 In the method for producing a tablet of the present invention, the obtained molded body is dried. The drying method is not limited as long as the solvent of the molded body evaporates. For example, freeze drying, reduced-pressure drying, air-blast drying, natural drying, or heat drying can be cited.

例如,採用加熱乾燥時,加熱溫度並無特別限定,例如優選為50至200℃,優選為80至180℃。加熱時間亦無特別限定,優選為10分鐘至3小時,更優選為30分鐘至2小時。 For example, when heating and drying are used, the heating temperature is not particularly limited. For example, it is preferably 50 to 200°C, and preferably 80 to 180°C. The heating time is also not particularly limited, but is preferably 10 minutes to 3 hours, more preferably 30 minutes to 2 hours.

然而,加熱溫度較高時,可縮短加熱時間,本行業技術人員可適當決定加熱溫度和加熱時間。 However, when the heating temperature is higher, the heating time can be shortened, and those skilled in the industry can appropriately determine the heating temperature and heating time.

此外,通過乾燥製程(3)獲得的片劑的水分含量並無特別限定,優選為0.01至20重量%,更優選為0.1至10重量%。 In addition, the moisture content of the tablet obtained by the drying process (3) is not particularly limited, and is preferably 0.01 to 20% by weight, more preferably 0.1 to 10% by weight.

【實施例】 [Example]

以下,藉由實施例具體說明本發明,但該說明並非用來限定本發明的範圍。 Hereinafter, the present invention will be described in detail through examples, but the description is not intended to limit the scope of the present invention.

《製造例1:多孔性球狀碳質物質的製造》 "Production Example 1: Production of Porous Spherical Carbonaceous Material"

與日本專利特許第3522708號(日本專利特開2002-308785號公報)的實施例1中記載的方法同樣地獲得多孔性球狀碳質物質。具體操作如下所示。 The porous spherical carbonaceous material was obtained in the same manner as the method described in Example 1 of Japanese Patent No. 3522708 (Japanese Patent Laid-Open No. 2002-308785). The specific operation is as follows.

將68kg石油類瀝青(軟化點210℃;喹啉不溶物1重量%以下;H/C原子比0.63)與32kg萘放入帶攪拌葉片且內容積為300L的耐壓容器中,在180℃下進行熔融混合後,冷卻到80至90℃擠出,獲得繩狀成型體。接著,將該繩狀成型體破碎為直徑與長度的比值約為1至2。 Put 68kg of petroleum-based asphalt (softening point 210℃; quinoline insoluble matter below 1% by weight; H/C atomic ratio 0.63) and 32kg naphthalene into a pressure vessel with a stirring blade and an inner volume of 300L, at 180℃ After being melt-mixed, it is cooled to 80 to 90°C and extruded to obtain a rope-shaped molded body. Next, the rope-shaped molded body is broken into a ratio of about 1 to 2 in diameter to length.

向溶解0.23重量%聚乙烯醇(皂化度88%)且加熱到93℃的水溶液中投入所述破碎物,通過攪拌分散而球狀化後,通過用水置換所述聚乙烯醇水溶液來進行冷卻,在20℃下冷卻3小時,使瀝青固化,並使萘結晶析出,獲得球狀瀝青成型體糊狀物。 The crushed material is added to an aqueous solution that dissolves 0.23% by weight of polyvinyl alcohol (88% of saponification degree) and is heated to 93°C. After stirring and dispersing to spheroidize, it is cooled by replacing the polyvinyl alcohol aqueous solution with water. Cooled at 20°C for 3 hours to solidify the pitch and crystallize naphthalene to obtain a spherical pitch molded body paste.

通過過濾除去大部分水後,用重量約為球狀瀝青成型體6倍的正己烷提取除去瀝青成型體中的萘。一邊使用流體床對如此獲得的 多孔性球狀瀝青通入加熱空氣,一邊升溫到235℃後,在235℃下保持1小時進行氧化,獲得遇熱不熔的多孔性球狀氧化瀝青。 After removing most of the water by filtration, the naphthalene in the pitch molded body is extracted and removed with n-hexane, which weighs about 6 times the weight of the spherical pitch molded body. While using the fluid bed The porous spherical pitch was heated to 235°C by passing heated air, and then kept at 235°C for 1 hour to oxidize to obtain porous spherical oxidized pitch that does not melt when heated.

然後,使用流體床在含50vol%水蒸氣的氮氣環境下對多孔性球狀氧化瀝青在900℃下進行170分鐘活化處理而獲得多孔性球狀活性炭,進而使用流體床在氧濃度為18.5vol%的氮氣與氧氣的混合氣體環境下對該多孔性球狀活性炭在470℃下進行3小時15分鐘氧化處理,接著使用流體床在氮氣環境下在900℃下進行17分鐘還原處理,獲得多孔性球狀碳質物質。在以下的藥理試驗例中使用如此獲得的多孔性球狀碳質物質作為球狀活性炭。 Then, the porous spherical oxidized pitch was activated for 170 minutes at 900°C using a fluid bed in a nitrogen environment containing 50 vol% water vapor to obtain porous spherical activated carbon, and then the fluid bed was used at an oxygen concentration of 18.5 vol% The porous spherical activated carbon was oxidized at 470°C for 3 hours and 15 minutes in a mixed gas environment of nitrogen and oxygen, and then reduced in a fluid bed at 900°C for 17 minutes in a nitrogen environment to obtain porous balls Like carbonaceous material. In the following pharmacological test examples, the porous spherical carbonaceous material thus obtained was used as the spherical activated carbon.

獲得的碳質材料的主要特性如下所示。 The main characteristics of the obtained carbonaceous material are as follows.

比表面積1300m2/g(BET法);細孔容積0.08mL/g Specific surface area 1300m 2 /g (BET method); pore volume 0.08mL/g

(通過水銀壓入法求出的細孔直徑為20至15000nm範圍的細孔容積);平均粒徑350μm;總酸基0.67meq/g;總鹼基0.54meq/g;壓壞強度31.2MPa;以及施加2MPa壓力時的變形率0.7%。 (The pore diameter calculated by mercury intrusion method is the pore volume in the range of 20 to 15000nm); the average particle size is 350μm; the total acid base is 0.67meq/g; the total base is 0.54meq/g; the crush strength is 31.2MPa; And the deformation rate when 2MPa pressure is applied is 0.7%.

《製造例2:多孔性球狀碳質物質的製造》 "Production Example 2: Production of Porous Spherical Carbonaceous Material"

與日本專利特開2005-314416號公報的實施例1中記載的方法同樣地獲得多孔性球狀碳質物質(表面改質球狀活性炭)。具體操作如下所示。 The porous spherical carbonaceous substance (surface-modified spherical activated carbon) was obtained in the same manner as the method described in Example 1 of JP 2005-314416 A. The specific operation is as follows.

將220g去離子交換水及58g甲基纖維素放入1L的可分離燒瓶,向該可分離燒瓶中適當添加105g苯乙烯、184g純度57%的二乙烯苯(57%的二乙烯苯與43%的乙烯基乙基苯)、1.68g 2,2'-偶氮雙(2,4-二甲基戊腈)、以及63g作為成孔劑的1-丁醇後,用氮氣置換系統內部,以200rpm攪拌該二相系統,加熱到55℃後,保持其狀態20小時。對獲得的樹脂進行過濾,用旋轉蒸發器進行乾燥後,使用減壓乾燥機通過蒸餾將1-丁醇從樹脂中除去,然後在90℃下減壓乾燥12小時,獲得平均粒徑180μm的球狀多孔性合成樹脂。多孔性合成樹脂的比表面積約為90m2/g。 Put 220g of deionized exchange water and 58g of methylcellulose into a 1L separable flask, and add 105g of styrene and 184g of divinylbenzene (57% divinylbenzene and 43%) with a purity of 57% into the separable flask. Of vinyl ethyl benzene), 1.68g of 2,2'-azobis(2,4-dimethylvaleronitrile), and 63g of 1-butanol as a pore-forming agent, then replace the inside of the system with nitrogen to The two-phase system was stirred at 200 rpm, and after heating to 55°C, the state was maintained for 20 hours. The obtained resin was filtered, dried with a rotary evaporator, 1-butanol was removed from the resin by distillation using a vacuum dryer, and then dried under reduced pressure at 90°C for 12 hours to obtain a ball with an average particle diameter of 180μm Shape porous synthetic resin. The specific surface area of the porous synthetic resin is approximately 90 m 2 /g.

將獲得的100g球狀多孔性合成樹脂放入帶多孔盤的反應管內,用縱型管狀爐進行不融化處理。不融化條件如下,以3L/min使乾燥空氣從反應管下部向上部流動,以5℃/h升溫到260℃後,通過在260℃下保持4小時,獲得球狀多孔性氧化樹脂。將球狀多孔性氧化樹脂在氮氣環境下在600℃下進行1小時熱處理後,使用流體床,在含64.5vol%水蒸氣的氮氣環境下,在820℃下進行10小時活化處理,獲得球狀活性炭。進而使用流體床在氧濃度為18.5vol%的氮氣與氧氣的混合氣體環境下對獲得的球狀活性炭在470℃下進行3小時15分鐘氧化處理,接著使用流體床在氮氣環境下在900℃下進行17分鐘還原處理,獲得表面改質球狀活性炭。 Put 100 g of the obtained spherical porous synthetic resin into a reaction tube with a porous disk, and perform a non-melting treatment in a vertical tubular furnace. The non-melting conditions were as follows. Dry air was flowed from the lower part of the reaction tube to the upper part at 3 L/min, the temperature was raised to 260 °C at 5 °C/h, and then maintained at 260 °C for 4 hours to obtain spherical porous oxide resin. After the spherical porous oxide resin is heat-treated at 600°C for 1 hour in a nitrogen environment, using a fluid bed, an activation treatment is performed at 820°C for 10 hours in a nitrogen environment containing 64.5vol% water vapor to obtain a spherical shape. Activated carbon. Furthermore, a fluid bed was used to oxidize the obtained spherical activated carbon at 470°C for 3 hours and 15 minutes in a mixed gas environment of nitrogen and oxygen with an oxygen concentration of 18.5 vol%, and then a fluid bed was used at 900°C in a nitrogen environment. The reduction treatment was carried out for 17 minutes to obtain surface-modified spherical activated carbon.

獲得的表面改質球狀活性炭的主要特性如下所示。 The main characteristics of the obtained surface-modified spherical activated carbon are as follows.

比表面積1763m2/g(BET法);細孔容積0.05mL/g Specific surface area 1763m 2 /g (BET method); pore volume 0.05mL/g

(通過水銀壓入法求出的細孔直徑為20至15000nm範圍的細孔容積);平均粒徑111μm(Dv50);總酸基0.59meq/g;總鹼基0.61meq/g;容積密度0.50g/cm3;壓壞強度436.5MPa;以及施加2MPa壓力時的變形率0.2%。 (The pore diameter is the pore volume in the range of 20 to 15000nm, as determined by mercury intrusion method); average particle size 111μm (Dv50); total acid groups 0.59meq/g; total bases 0.61meq/g; bulk density 0.50 g/cm 3 ; crushing strength 436.5MPa; and the deformation rate when 2MPa pressure is applied 0.2%.

另外,本說明書中,雖然沒有記載使用製造例2中獲得的球狀活性炭製作片劑的實施例,但是與製造例1中獲得的球狀活性炭同樣地可獲得本發明的片劑。 In addition, in this specification, although there is no description of an example of producing a tablet using the spherical activated carbon obtained in Production Example 2, the tablet of the present invention can be obtained in the same manner as the spherical activated carbon obtained in Production Example 1.

《實施例1》 "Example 1"

將製造例1中獲得的500g球狀活性炭投入轉動流動鍍膜裝置(MP-01),噴出表1所示處方的噴液霧。然後,進行乾燥,獲得535.5g覆蓋品。向獲得的覆蓋品中以1g覆蓋品對應1.2mL的比例添加乙醇/水混合液(6:4)後,使用低壓成型機進行成型,並進行乾燥,從而獲得直徑15mm的片劑。 500 g of spherical activated carbon obtained in Production Example 1 was put into a rotary flow coating device (MP-01), and spray mist of the prescription shown in Table 1 was sprayed. Then, it dried to obtain 535.5 g of mulch. After adding an ethanol/water mixed solution (6:4) at a ratio of 1 g of the covering product to 1.2 mL to the obtained covering product, it was molded using a low-pressure forming machine and dried to obtain tablets with a diameter of 15 mm.

表2示出覆蓋品的回收率。覆蓋品的回收率(%)通過獲得的覆蓋品量/覆蓋品的理論量×100進行計算。上述回收率越高,口服給藥用球狀吸附炭的收穫率越高。 Table 2 shows the recovery rate of the covering product. The recovery rate (%) of mulch is calculated by the amount of mulch obtained/theoretical amount of mulch×100. The higher the above recovery rate, the higher the harvest rate of the spherical adsorption charcoal for oral administration.

使用X射線CT顯微鏡對獲得的片劑進行解析後,獲得表54所示片劑的體積率及表55所示片劑內添加劑體積率的結果。 After analyzing the obtained tablets using an X-ray CT microscope, the results of the volume ratio of the tablets shown in Table 54 and the volume ratio of additives in the tablets shown in Table 55 were obtained.

Figure 106110616-A0202-12-0028-1
Figure 106110616-A0202-12-0028-1

Figure 106110616-A0202-12-0028-2
Figure 106110616-A0202-12-0028-2

《實施例2》 "Example 2"

將製造例1中獲得的500g球狀活性炭投入轉動流動鍍膜裝置(MP-01),噴出表3所示處方的噴液霧。然後,進行乾燥,獲得751.78g覆蓋品。向獲得的覆蓋品中以1g覆蓋品對應1.2 mL的比例添加乙醇/水混合液(6:4)後,使用低壓成型機進行成型,並進行乾燥,從而獲得直徑12mm的片劑。 500 g of the spherical activated carbon obtained in Production Example 1 was put into the rotary flow coating device (MP-01), and the spray mist of the prescription shown in Table 3 was sprayed. Then, it dried to obtain 751.78 g of mulch. Corresponds to 1.2 of the obtained coverings with 1g coverings After adding an ethanol/water mixed solution (6:4) in a ratio of mL, it was molded using a low-pressure molding machine and dried to obtain tablets with a diameter of 12 mm.

表4示出覆蓋品的回收率。使用X射線CT顯微鏡對獲得的片劑進行解析後,獲得表54所示片劑的體積率及表55所示片劑內添加劑體積率的結果。 Table 4 shows the recovery rate of the covering product. After analyzing the obtained tablets using an X-ray CT microscope, the results of the volume ratio of the tablets shown in Table 54 and the volume ratio of additives in the tablets shown in Table 55 were obtained.

Figure 106110616-A0202-12-0029-3
Figure 106110616-A0202-12-0029-3

Figure 106110616-A0202-12-0029-4
Figure 106110616-A0202-12-0029-4

《實施例3》 "Example 3"

將製造例1中獲得的500g球狀活性炭投入轉動流動鍍膜裝置(MP-01),噴出表5所示處方的噴液霧。然後,進行乾燥,獲得512.5g覆蓋品。將獲得的覆蓋品填充到Teflon(註冊商 標)製成型模具(直徑12mm、深度10.2mm、R16mm),以1g覆蓋品對應0.9mL的比例添加水後,用上部安裝到攪拌機的成型棒輕輕壓縮而修整片劑表面,並進行乾燥,從而獲得直徑12mm的片劑。 500 g of spherical activated carbon obtained in Production Example 1 was put into a rotary flow coating device (MP-01), and spray mist of the prescription shown in Table 5 was sprayed. Then, it dried to obtain 512.5 g of mulch. Fill the obtained coverings into Teflon (registrar Standard) Forming mold (diameter 12mm, depth 10.2mm, R16mm), after adding water at a ratio of 1g covering to 0.9mL, gently compress it with a molding rod attached to the mixer to trim the surface of the tablet and dry it , Thereby obtaining tablets with a diameter of 12 mm.

表6示出覆蓋品的回收率。使用X射線CT顯微鏡對獲得的片劑進行解析後,獲得表54所示片劑的體積率及表55所示片劑內添加劑體積率的結果。 Table 6 shows the recovery rate of the covering product. After analyzing the obtained tablets using an X-ray CT microscope, the results of the volume ratio of the tablets shown in Table 54 and the volume ratio of additives in the tablets shown in Table 55 were obtained.

Figure 106110616-A0202-12-0030-5
Figure 106110616-A0202-12-0030-5

Figure 106110616-A0202-12-0030-6
Figure 106110616-A0202-12-0030-6

《實施例4》 "Example 4"

將製造例1中獲得的500g球狀活性炭投入轉動流動鍍膜裝置(MP-01),噴出表7所示處方的噴液霧。然後,進行乾 燥,獲得500.0g覆蓋品。向獲得的覆蓋品中以1g覆蓋品對應1.9mL的比例添加乙醇/水混合液(4:6)後,使用低壓成型機進行成型,並進行乾燥,從而獲得直徑12mm的片劑。 500 g of the spherical activated carbon obtained in Production Example 1 was put into the rotary flow coating device (MP-01), and the spray mist of the prescription shown in Table 7 was sprayed. Then, dry After drying, 500.0 g of mulch was obtained. After adding an ethanol/water mixture (4:6) at a ratio of 1 g of the covering product to 1.9 mL to the obtained covering product, it was molded using a low-pressure molding machine and dried to obtain a tablet with a diameter of 12 mm.

表8示出覆蓋品的回收率。使用X射線CT顯微鏡對獲得的片劑進行解析後,獲得表54所示片劑的體積率及表55所示片劑內添加劑體積率的結果。 Table 8 shows the recovery rate of the covering product. After analyzing the obtained tablets using an X-ray CT microscope, the results of the volume ratio of the tablets shown in Table 54 and the volume ratio of additives in the tablets shown in Table 55 were obtained.

Figure 106110616-A0202-12-0031-7
Figure 106110616-A0202-12-0031-7

Figure 106110616-A0202-12-0031-8
Figure 106110616-A0202-12-0031-8

《實施例5》 "Example 5"

將製造例1中獲得的500g球狀活性炭投入轉動流動鍍膜裝置(MP-01),噴出表9所示處方的噴液霧。然後,進行乾燥,獲得506.8g覆蓋品。向獲得的覆蓋品中以1g覆蓋品對應1.4 mL的比例添加乙醇/水混合液(5:5)後,使用低壓成型機進行成型,並進行乾燥,從而獲得直徑12mm的片劑。 500 g of the spherical activated carbon obtained in Production Example 1 was put into the rotary flow coating device (MP-01), and the spray mist of the prescription shown in Table 9 was sprayed. Then, it dried to obtain 506.8 g of mulch. Corresponds to 1.4 of the obtained coverings with 1g coverings After adding an ethanol/water mixture (5:5) in a ratio of mL, it was molded using a low-pressure molding machine and dried to obtain tablets with a diameter of 12 mm.

表10示出覆蓋品的回收率。使用X射線CT顯微鏡對獲得的片劑進行解析後,獲得表54所示片劑的體積率及表55所示片劑內添加劑體積率的結果。 Table 10 shows the recovery rate of the covering product. After analyzing the obtained tablets using an X-ray CT microscope, the results of the volume ratio of the tablets shown in Table 54 and the volume ratio of additives in the tablets shown in Table 55 were obtained.

Figure 106110616-A0202-12-0032-9
Figure 106110616-A0202-12-0032-9

Figure 106110616-A0202-12-0032-10
Figure 106110616-A0202-12-0032-10

《實施例6》 "Example 6"

將製造例1中獲得的500g球狀活性炭投入轉動流動鍍膜裝置(MP-01),噴出表11所示處方的噴液霧。然後,進行乾燥,獲得564.4g覆蓋品。向獲得的覆蓋品中以1g覆蓋品對應1.1 mL的比例添加乙醇/水混合液(6:4)後,使用低壓成型機進行成型,並進行乾燥,從而獲得直徑12mm的片劑。 500 g of spherical activated carbon obtained in Production Example 1 was put into a rotary flow coating device (MP-01), and spray mist of the prescription shown in Table 11 was sprayed. Then, it dried to obtain 564.4 g of mulch. Corresponds to 1.1 of the obtained coverings with 1g coverings After adding an ethanol/water mixed solution (6:4) in a ratio of mL, it was molded using a low-pressure molding machine and dried to obtain tablets with a diameter of 12 mm.

表12示出覆蓋品的回收率。使用X射線CT顯微鏡對獲得的片劑進行解析後,獲得表54所示片劑的體積率及表55所示片劑內添加劑體積率的結果。 Table 12 shows the recovery rate of the covering product. After analyzing the obtained tablets using an X-ray CT microscope, the results of the volume ratio of the tablets shown in Table 54 and the volume ratio of additives in the tablets shown in Table 55 were obtained.

Figure 106110616-A0202-12-0033-11
Figure 106110616-A0202-12-0033-11

Figure 106110616-A0202-12-0033-12
Figure 106110616-A0202-12-0033-12

《實施例7》 "Example 7"

將製造例1中獲得的500g球狀活性炭投入轉動流動鍍膜裝置(MP-01),噴出表13所示處方的噴液霧。然後,進行乾燥,獲得530.8g覆蓋品。向獲得的覆蓋品中以1g覆蓋品對應1.2 mL的比例添加乙醇/水混合液(2:8)後,使用低壓成型機進行成型,並進行乾燥,從而獲得直徑12mm的片劑。 500 g of spherical activated carbon obtained in Production Example 1 was put into a rotary flow coating device (MP-01), and spray mist of the prescription shown in Table 13 was sprayed. Then, drying was performed to obtain 530.8 g of a covering product. Corresponds to 1.2 of the obtained coverings with 1g coverings After adding an ethanol/water mixture (2:8) in a ratio of mL, molding was performed using a low-pressure molding machine and dried to obtain tablets with a diameter of 12 mm.

表14示出覆蓋品的回收率。使用X射線CT顯微鏡對獲得的片劑進行解析後,獲得表54所示片劑的體積率及表55所示片劑內添加劑體積率的結果。 Table 14 shows the recovery rate of the covering product. After analyzing the obtained tablets using an X-ray CT microscope, the results of the volume ratio of the tablets shown in Table 54 and the volume ratio of additives in the tablets shown in Table 55 were obtained.

Figure 106110616-A0202-12-0034-13
Figure 106110616-A0202-12-0034-13

Figure 106110616-A0202-12-0034-14
Figure 106110616-A0202-12-0034-14

《實施例8》 "Example 8"

將製造例1中獲得的500g球狀活性炭投入轉動流動鍍膜裝置(MP-01),噴出表15所示處方的噴液霧。然後,進行乾燥,獲得497.8g覆蓋品。向獲得的覆蓋品中以1g覆蓋品對應1.1 mL的比例添加乙醇/水混合液(5:5)後,使用低壓成型機進行成型,並進行乾燥,從而獲得直徑12mm的片劑。 500 g of spherical activated carbon obtained in Production Example 1 was put into a rotary flow coating device (MP-01), and a spray mist of the prescription shown in Table 15 was sprayed. Then, it dried to obtain 497.8 g of mulch. Corresponds to 1.1 of the obtained coverings with 1g coverings After adding an ethanol/water mixture (5:5) in a ratio of mL, it was molded using a low-pressure molding machine and dried to obtain tablets with a diameter of 12 mm.

表16示出覆蓋品的回收率。使用X射線CT顯微鏡對獲得的片劑進行解析後,獲得表54所示片劑的體積率及表55所示片劑內添加劑體積率的結果。 Table 16 shows the recovery rate of the covering product. After analyzing the obtained tablets using an X-ray CT microscope, the results of the volume ratio of the tablets shown in Table 54 and the volume ratio of additives in the tablets shown in Table 55 were obtained.

Figure 106110616-A0202-12-0035-15
Figure 106110616-A0202-12-0035-15

Figure 106110616-A0202-12-0035-16
Figure 106110616-A0202-12-0035-16

《實施例9》 "Example 9"

將製造例1中獲得的500g球狀活性炭投入轉動流動鍍膜裝置(MP-01),噴出表17所示處方的噴液霧。然後,進行乾燥,獲得518.1g覆蓋品。向獲得的覆蓋品中以1g覆蓋品對應1.0 mL的比例添加乙醇/水混合液(4:6)後,使用低壓成型機進行成型,並進行乾燥,從而獲得直徑12mm的片劑。 500 g of spherical activated carbon obtained in Production Example 1 was put into a rotary flow coating device (MP-01), and spray mist of the prescription shown in Table 17 was sprayed. Then, it dried to obtain 518.1 g of mulch. Corresponds to 1.0 of the obtained coverings with 1g coverings After adding an ethanol/water mixture (4:6) in a ratio of mL, it was molded using a low-pressure molding machine and dried to obtain tablets with a diameter of 12 mm.

表18示出覆蓋品的回收率。使用X射線CT顯微鏡對獲得的片劑進行解析後,獲得表54所示片劑的體積率及表55所示片劑內添加劑體積率的結果。 Table 18 shows the recovery rate of the covering product. After analyzing the obtained tablets using an X-ray CT microscope, the results of the volume ratio of the tablets shown in Table 54 and the volume ratio of additives in the tablets shown in Table 55 were obtained.

Figure 106110616-A0202-12-0036-17
Figure 106110616-A0202-12-0036-17

Figure 106110616-A0202-12-0036-18
Figure 106110616-A0202-12-0036-18

《實施例10》 "Example 10"

將製造例1中獲得的500g球狀活性炭投入轉動流動鍍膜裝置(MP-01),噴出表19所示處方的噴液霧。然後,進行乾燥,獲得537.3g覆蓋品。向獲得的覆蓋品中以1g覆蓋品對應1.4 mL的比例添加乙醇/水混合液(1:9)後,使用低壓成型機進行成型,並進行乾燥,從而獲得直徑12mm的片劑。 500 g of spherical activated carbon obtained in Production Example 1 was put into a rotary flow coating device (MP-01), and a spray mist of the prescription shown in Table 19 was sprayed. Then, it dried to obtain 537.3 g of mulch. Corresponds to 1.4 of the obtained coverings with 1g coverings After adding an ethanol/water mixture (1:9) in a ratio of mL, molding was performed using a low-pressure molding machine and dried to obtain tablets with a diameter of 12 mm.

表20示出覆蓋品的回收率。使用X射線CT顯微鏡對獲得的片劑進行解析後,獲得表54所示片劑的體積率及表55所示片劑內添加劑體積率的結果。 Table 20 shows the recovery rate of the covering product. After analyzing the obtained tablets using an X-ray CT microscope, the results of the volume ratio of the tablets shown in Table 54 and the volume ratio of additives in the tablets shown in Table 55 were obtained.

Figure 106110616-A0202-12-0037-19
Figure 106110616-A0202-12-0037-19

Figure 106110616-A0202-12-0037-20
Figure 106110616-A0202-12-0037-20

《實施例11》 "Example 11"

將製造例1中獲得的500g球狀活性炭投入轉動流動鍍膜裝置(MP-01),噴出表21所示處方的噴液霧。然後,進行乾燥,獲得525.2g覆蓋品。向獲得的覆蓋品中以1g覆蓋品應對1.3 mL的比例添加乙醇/水混合液(1:9)後,使用低壓成型機進行成型,並進行乾燥,從而獲得直徑12mm的片劑。 500 g of the spherical activated carbon obtained in Production Example 1 was put into the rotary flow coating device (MP-01), and the spray mist of the prescription shown in Table 21 was sprayed. Then, it dried to obtain 525.2 g of mulch. Cope with 1.3 of the obtained covering with 1g covering After adding an ethanol/water mixture (1:9) in a ratio of mL, molding was performed using a low-pressure molding machine and dried to obtain tablets with a diameter of 12 mm.

表22示出覆蓋品的回收率。使用X射線CT顯微鏡對獲得的片劑進行解析後,獲得表54所示片劑的體積率及表55所示片劑內添加劑體積率的結果。 Table 22 shows the recovery rate of the covering product. After analyzing the obtained tablets using an X-ray CT microscope, the results of the volume ratio of the tablets shown in Table 54 and the volume ratio of additives in the tablets shown in Table 55 were obtained.

Figure 106110616-A0202-12-0038-21
Figure 106110616-A0202-12-0038-21

Figure 106110616-A0202-12-0038-22
Figure 106110616-A0202-12-0038-22

《實施例12》 "Example 12"

將製造例1中獲得的500g球狀活性炭投入轉動流動鍍膜裝置(MP-01),噴出表23所示處方的噴液霧。然後,進行乾燥,獲得622.6g覆蓋品。向獲得的覆蓋品中以1g覆蓋品對應0.6 mL的比例添加乙醇/水混合液(1:9)後,使用低壓成型機進行成型,並進行乾燥,從而獲得直徑12mm的片劑。 500 g of spherical activated carbon obtained in Production Example 1 was put into a rotary flow coating device (MP-01), and a spray mist of the prescription shown in Table 23 was sprayed. Then, it dried to obtain 622.6 g of mulch. 1g of coverings corresponds to 0.6 of the obtained coverings After adding an ethanol/water mixture (1:9) in a ratio of mL, molding was performed using a low-pressure molding machine and dried to obtain tablets with a diameter of 12 mm.

表24示出覆蓋品的回收率。使用X射線CT顯微鏡對獲得的片劑進行解析後,獲得表54所示片劑的體積率及表55所示片劑內添加劑體積率的結果。 Table 24 shows the recovery rate of the covering product. After analyzing the obtained tablets using an X-ray CT microscope, the results of the volume ratio of the tablets shown in Table 54 and the volume ratio of additives in the tablets shown in Table 55 were obtained.

Figure 106110616-A0202-12-0039-23
Figure 106110616-A0202-12-0039-23

Figure 106110616-A0202-12-0039-24
Figure 106110616-A0202-12-0039-24

《實施例13》 "Example 13"

將製造例1中獲得的500g球狀活性炭投入轉動流動鍍膜裝置(MP-01),噴出表25所示處方的噴液霧。然後,進行乾燥,獲得548.3g覆蓋品。向獲得的覆蓋品中以1g覆蓋品對應1.2 mL的比例添加乙醇/水混合液(1:9)後,使用低壓成型機進行成型,並進行乾燥,從而獲得直徑12mm的片劑。 500 g of spherical activated carbon obtained in Production Example 1 was put into a rotary flow coating device (MP-01), and a spray mist of the prescription shown in Table 25 was sprayed. Then, it dried to obtain 548.3 g of mulch. Corresponds to 1.2 of the obtained coverings with 1g coverings After adding an ethanol/water mixture (1:9) in a ratio of mL, molding was performed using a low-pressure molding machine and dried to obtain tablets with a diameter of 12 mm.

表26示出覆蓋品的回收率。使用X射線CT顯微鏡對獲得的片劑進行解析後,獲得表54所示片劑的體積率及表55所示片劑內添加劑體積率的結果。 Table 26 shows the recovery rate of the cover product. After analyzing the obtained tablets using an X-ray CT microscope, the results of the volume ratio of the tablets shown in Table 54 and the volume ratio of additives in the tablets shown in Table 55 were obtained.

Figure 106110616-A0202-12-0040-25
Figure 106110616-A0202-12-0040-25

Figure 106110616-A0202-12-0040-26
Figure 106110616-A0202-12-0040-26

《實施例14》 "Example 14"

將製造例1中獲得的500g球狀活性炭投入轉動流動鍍膜裝置(MP-01),噴出表27所示處方的噴液霧。然後,進行乾燥,獲得524.0g覆蓋品。向獲得的覆蓋品中以1g覆蓋品對應1.1 mL的比例添加乙醇/水混合液(1:9)後,使用低壓成型機進行成型,並進行乾燥,從而獲得直徑12mm的片劑。 500 g of the spherical activated carbon obtained in Production Example 1 was put into the rotary flow coating device (MP-01), and the spray mist of the prescription shown in Table 27 was sprayed. Then, it dried and obtained 524.0g of mulches. Corresponds to 1.1 of the obtained coverings with 1g coverings After adding an ethanol/water mixture (1:9) in a ratio of mL, molding was performed using a low-pressure molding machine and dried to obtain tablets with a diameter of 12 mm.

表28示出覆蓋品的回收率。使用X射線CT顯微鏡對獲得的片劑進行解析後,獲得表54所示片劑的體積率及表55所示片劑內添加劑體積率的結果。 Table 28 shows the recovery rate of the cover product. After analyzing the obtained tablets using an X-ray CT microscope, the results of the volume ratio of the tablets shown in Table 54 and the volume ratio of additives in the tablets shown in Table 55 were obtained.

Figure 106110616-A0202-12-0041-27
Figure 106110616-A0202-12-0041-27

Figure 106110616-A0202-12-0041-28
Figure 106110616-A0202-12-0041-28

《實施例15》 "Example 15"

將製造例1中獲得的500g球狀活性炭投入轉動流動鍍膜裝置(MP-01),噴出表29所示處方的噴液霧。然後,進行乾燥,獲得543.5g覆蓋品。向獲得的覆蓋品中以1g覆蓋品對應1.1 mL的比例添加乙醇/水混合液(4:6)後,使用低壓成型機進行成型,並進行乾燥,從而獲得直徑12mm的片劑。 500 g of the spherical activated carbon obtained in Production Example 1 was put into the rotary flow coating device (MP-01), and the spray mist of the prescription shown in Table 29 was sprayed. Then, it dried to obtain 543.5 g of mulch. Corresponds to 1.1 of the obtained coverings with 1g coverings After adding an ethanol/water mixture (4:6) in a ratio of mL, it was molded using a low-pressure molding machine and dried to obtain tablets with a diameter of 12 mm.

表30示出覆蓋品的回收率。使用X射線CT顯微鏡對獲得的片劑進行解析後,獲得表54所示片劑的體積率及表55所示片劑內添加劑體積率的結果。 Table 30 shows the recovery rate of the covering product. After analyzing the obtained tablets using an X-ray CT microscope, the results of the volume ratio of the tablets shown in Table 54 and the volume ratio of additives in the tablets shown in Table 55 were obtained.

Figure 106110616-A0202-12-0042-29
Figure 106110616-A0202-12-0042-29

Figure 106110616-A0202-12-0042-30
Figure 106110616-A0202-12-0042-30

《實施例16》 "Example 16"

將製造例1中獲得的500g球狀活性炭投入轉動流動鍍膜裝置(MP-01),噴出表31所示處方的噴液霧。然後,進行乾燥,獲得531.9g覆蓋品。向獲得的覆蓋品中以1g覆蓋品對應1.2 mL的比例添加乙醇/水混合液(5:5)後,使用低壓成型機進行成型,並進行乾燥,從而獲得直徑12mm的片劑。 500 g of spherical activated carbon obtained in Production Example 1 was put into a rotary flow coating device (MP-01), and spray mist of the prescription shown in Table 31 was sprayed. Then, it dried to obtain 531.9 g of mulch. Corresponds to 1.2 of the obtained coverings with 1g coverings After adding an ethanol/water mixture (5:5) in a ratio of mL, it was molded using a low-pressure molding machine and dried to obtain tablets with a diameter of 12 mm.

表32示出覆蓋品的回收率。使用X射線CT顯微鏡對獲得的片劑進行解析後,獲得表54所示片劑的體積率及表55所示片劑內添加劑體積率的結果。 Table 32 shows the recovery rate of the covering product. After analyzing the obtained tablets using an X-ray CT microscope, the results of the volume ratio of the tablets shown in Table 54 and the volume ratio of additives in the tablets shown in Table 55 were obtained.

Figure 106110616-A0202-12-0043-31
Figure 106110616-A0202-12-0043-31

Figure 106110616-A0202-12-0043-32
Figure 106110616-A0202-12-0043-32

《實施例17》 "Example 17"

將製造例1中獲得的500g球狀活性炭投入轉動流動鍍膜裝置(MP-01),噴出表33所示處方的噴液霧。然後,進行乾燥,獲得543.3g覆蓋品。向獲得的覆蓋品中以1g覆蓋品對應1.2 mL的比例添加乙醇/水混合液(4:6)後,使用低壓成型機進行成型,並進行乾燥,從而獲得直徑12mm的片劑。 500 g of spherical activated carbon obtained in Production Example 1 was put into a rotary flow coating device (MP-01), and a spray mist of the prescription shown in Table 33 was sprayed. Then, it dried to obtain 543.3 g of mulch. Corresponds to 1.2 of the obtained coverings with 1g coverings After adding an ethanol/water mixture (4:6) in a ratio of mL, it was molded using a low-pressure molding machine and dried to obtain tablets with a diameter of 12 mm.

表34示出覆蓋品的回收率。使用X射線CT顯微鏡對獲得的片劑進行解析後,獲得表54所示片劑的體積率及表55所示片劑內添加劑體積率的結果。 Table 34 shows the recovery rate of the cover product. After analyzing the obtained tablets using an X-ray CT microscope, the results of the volume ratio of the tablets shown in Table 54 and the volume ratio of additives in the tablets shown in Table 55 were obtained.

Figure 106110616-A0202-12-0044-33
Figure 106110616-A0202-12-0044-33

Figure 106110616-A0202-12-0044-34
Figure 106110616-A0202-12-0044-34

《實施例18》 "Example 18"

將製造例1中獲得的500g球狀活性炭投入轉動流動鍍膜裝置(MP-01),噴出表35所示處方的噴液霧。然後,進行乾燥,獲得502.9g覆蓋品。向獲得的覆蓋品中以1g覆蓋品對應1.4 mL的比例添加乙醇/水混合液(6:4)後,使用低壓成型機進行成型,並進行乾燥,從而獲得直徑12mm的片劑。 500 g of the spherical activated carbon obtained in Production Example 1 was put into the rotary flow coating device (MP-01), and the spray mist of the prescription shown in Table 35 was sprayed. Then, it dried to obtain 502.9 g of mulch. Corresponds to 1.4 of the obtained coverings with 1g coverings After adding an ethanol/water mixed solution (6:4) in a ratio of mL, it was molded using a low-pressure molding machine and dried to obtain tablets with a diameter of 12 mm.

表36示出覆蓋品的回收率。使用X射線CT顯微鏡對獲得的片劑進行解析後,獲得表54所示片劑的體積率及表55所示片劑內添加劑體積率的結果。 Table 36 shows the recovery rate of the cover product. After analyzing the obtained tablets using an X-ray CT microscope, the results of the volume ratio of the tablets shown in Table 54 and the volume ratio of additives in the tablets shown in Table 55 were obtained.

Figure 106110616-A0202-12-0045-35
Figure 106110616-A0202-12-0045-35

Figure 106110616-A0202-12-0045-36
Figure 106110616-A0202-12-0045-36

《實施例19》 "Example 19"

將製造例1中獲得的500g球狀活性炭投入轉動流動鍍膜裝置(MP-01),噴出表37所示處方的噴液霧。然後,進行乾燥,獲得515.4g覆蓋品。向獲得的覆蓋品中以1g覆蓋品對應1.2 mL的比例添加乙醇/水混合液(6:4)後,使用低壓成型機進行成型,並進行乾燥,從而獲得直徑12mm的片劑。 500 g of spherical activated carbon obtained in Production Example 1 was put into a rotary flow coating device (MP-01), and a spray mist of the prescription shown in Table 37 was sprayed. Then, drying was performed to obtain 515.4 g of a covering product. Corresponds to 1.2 of the obtained coverings with 1g coverings After adding an ethanol/water mixed solution (6:4) in a ratio of mL, it was molded using a low-pressure molding machine and dried to obtain tablets with a diameter of 12 mm.

表38示出覆蓋品的回收率。使用X射線CT顯微鏡對獲得的片劑進行解析後,獲得表54所示片劑的體積率及表55所示片劑內添加劑體積率的結果。 Table 38 shows the recovery rate of the cover product. After analyzing the obtained tablets using an X-ray CT microscope, the results of the volume ratio of the tablets shown in Table 54 and the volume ratio of additives in the tablets shown in Table 55 were obtained.

Figure 106110616-A0202-12-0046-37
Figure 106110616-A0202-12-0046-37

Figure 106110616-A0202-12-0046-38
Figure 106110616-A0202-12-0046-38

《實施例20》 "Example 20"

將製造例1中獲得的500g球狀活性炭投入轉動流動鍍膜裝置(MP-01),噴出表39所示處方的噴液霧。然後,進行乾燥,獲得530.8g覆蓋品。向獲得的覆蓋品中以1g覆蓋品對應1.4 mL的比例添加乙醇/水混合液(6:4)後,使用低壓成型機進行成型,並進行乾燥,從而獲得直徑12mm的片劑。 500 g of spherical activated carbon obtained in Production Example 1 was put into a rotary flow coating device (MP-01), and a spray mist of the prescription shown in Table 39 was sprayed. Then, drying was performed to obtain 530.8 g of a covering product. Corresponds to 1.4 of the obtained coverings with 1g coverings After adding an ethanol/water mixed solution (6:4) in a ratio of mL, it was molded using a low-pressure molding machine and dried to obtain tablets with a diameter of 12 mm.

表40示出覆蓋品的回收率。使用X射線CT顯微鏡對獲得的片劑進行解析後,獲得表54所示片劑的體積率及表55所示片劑內添加劑體積率的結果。 Table 40 shows the recovery rate of the covering product. After analyzing the obtained tablets using an X-ray CT microscope, the results of the volume ratio of the tablets shown in Table 54 and the volume ratio of additives in the tablets shown in Table 55 were obtained.

Figure 106110616-A0202-12-0047-39
Figure 106110616-A0202-12-0047-39

Figure 106110616-A0202-12-0047-40
Figure 106110616-A0202-12-0047-40

《實施例21》 "Example 21"

將製造例1中獲得的500g球狀活性炭投入轉動流動鍍膜裝置(MP-01),噴出表41所示處方的噴液霧。然後,進行乾燥,獲得552.0g覆蓋品。向獲得的覆蓋品中以1g覆蓋品對應1.1 mL的比例添加乙醇/水混合液(1:9)後,使用低壓成型機進行成型,並進行乾燥,從而獲得直徑12mm的片劑。 500 g of spherical activated carbon obtained in Production Example 1 was put into a rotary flow coating device (MP-01), and spray mist of the prescription shown in Table 41 was sprayed. Then, it dried to obtain 552.0 g of mulch. Corresponds to 1.1 of the obtained coverings with 1g coverings After adding an ethanol/water mixture (1:9) in a ratio of mL, molding was performed using a low-pressure molding machine and dried to obtain tablets with a diameter of 12 mm.

表42示出覆蓋品的回收率。使用X射線CT顯微鏡對獲得的片劑進行解析後,獲得表54所示片劑的體積率及表55所示片劑內添加劑體積率的結果。 Table 42 shows the recovery rate of the covering. After analyzing the obtained tablets using an X-ray CT microscope, the results of the volume ratio of the tablets shown in Table 54 and the volume ratio of additives in the tablets shown in Table 55 were obtained.

Figure 106110616-A0202-12-0048-41
Figure 106110616-A0202-12-0048-41

Figure 106110616-A0202-12-0048-42
Figure 106110616-A0202-12-0048-42

《實施例22》 "Example 22"

將製造例1中獲得的500g球狀活性炭投入轉動流動鍍膜裝置(MP-01),噴出表43所示處方的噴液霧。然後,進行乾燥,獲得490.6g覆蓋品。向獲得的覆蓋品中以1g覆蓋品對應1.1 mL的比例添加乙醇/水混合液(6:4)後,使用低壓成型機進行成型,並進行乾燥,從而獲得直徑12mm的片劑。 500 g of spherical activated carbon obtained in Production Example 1 was put into a rotary flow coating device (MP-01), and a spray mist of the prescription shown in Table 43 was sprayed. Then, it dried to obtain 490.6 g of mulch. Corresponds to 1.1 of the obtained coverings with 1g coverings After adding an ethanol/water mixed solution (6:4) in a ratio of mL, it was molded using a low-pressure molding machine and dried to obtain tablets with a diameter of 12 mm.

表44示出覆蓋品的回收率。使用X射線CT顯微鏡對獲得的片劑進行解析後,獲得表54所示片劑的體積率及表55所示片劑內添加劑體積率的結果。 Table 44 shows the recovery rate of the covering product. After analyzing the obtained tablets using an X-ray CT microscope, the results of the volume ratio of the tablets shown in Table 54 and the volume ratio of additives in the tablets shown in Table 55 were obtained.

Figure 106110616-A0202-12-0049-43
Figure 106110616-A0202-12-0049-43

Figure 106110616-A0202-12-0049-44
Figure 106110616-A0202-12-0049-44

《實施例23》 "Example 23"

將製造例1中獲得的500g球狀活性炭投入轉動流動鍍膜裝置(MP-01),噴出表45所示處方的噴液霧。然後,進行乾燥,獲得545.5g覆蓋品。向獲得的覆蓋品中以1g覆蓋品對應1.1 mL的比例添加乙醇/水混合液(6:4)後,使用低壓成型機進行成型,並進行乾燥,從而獲得直徑12mm的片劑。 500 g of spherical activated carbon obtained in Production Example 1 was put into a rotary flow coating device (MP-01), and spray mist of the prescription shown in Table 45 was sprayed. Then, it dried to obtain 545.5 g of mulch. Corresponds to 1.1 of the obtained coverings with 1g coverings After adding an ethanol/water mixed solution (6:4) in a ratio of mL, it was molded using a low-pressure molding machine and dried to obtain tablets with a diameter of 12 mm.

表46示出覆蓋品的回收率。使用X射線CT顯微鏡對獲得的片劑進行解析後,獲得表54所示片劑的體積率及表55所示片劑內添加劑體積率的結果。 Table 46 shows the recovery rate of the cover product. After analyzing the obtained tablets using an X-ray CT microscope, the results of the volume ratio of the tablets shown in Table 54 and the volume ratio of additives in the tablets shown in Table 55 were obtained.

Figure 106110616-A0202-12-0050-45
Figure 106110616-A0202-12-0050-45

Figure 106110616-A0202-12-0050-46
Figure 106110616-A0202-12-0050-46

《實施例24》 "Example 24"

將製造例1中獲得的500g球狀活性炭投入轉動流動鍍膜裝置(MP-01),噴出表47所示處方的噴液霧。然後,進行乾燥,獲得516.4g覆蓋品。向獲得的覆蓋品中以1g覆蓋品對應1.0 mL的比例添加乙醇/水混合液(1:9)後,使用低壓成型機進行成型,並進行乾燥,從而獲得直徑12mm的片劑。 500 g of spherical activated carbon obtained in Production Example 1 was put into a rotary flow coating device (MP-01), and a spray mist of the prescription shown in Table 47 was sprayed. Then, it dried to obtain 516.4 g of mulch. Corresponds to 1.0 of the obtained coverings with 1g coverings After adding an ethanol/water mixture (1:9) in a ratio of mL, molding was performed using a low-pressure molding machine and dried to obtain tablets with a diameter of 12 mm.

表48示出覆蓋品的回收率。使用X射線CT顯微鏡對獲得的片劑進行解析後,獲得表54所示片劑的體積率及表55所示片劑內添加劑體積率的結果。 Table 48 shows the recovery rate of the covering product. After analyzing the obtained tablets using an X-ray CT microscope, the results of the volume ratio of the tablets shown in Table 54 and the volume ratio of additives in the tablets shown in Table 55 were obtained.

Figure 106110616-A0202-12-0051-47
Figure 106110616-A0202-12-0051-47

Figure 106110616-A0202-12-0051-48
Figure 106110616-A0202-12-0051-48

《實施例25》 "Example 25"

將製造例1中獲得的500g球狀活性炭投入轉動流動鍍膜裝置(MP-01),噴出表49所示處方的噴液霧。然後,進行乾燥,獲得533.3g覆蓋品。向獲得的覆蓋品中以1g覆蓋品對應1.4 mL的比例添加乙醇/水混合液(6:4)後,使用低壓成型機進行成型,並進行乾燥,從而獲得直徑12mm的片劑。 500 g of spherical activated carbon obtained in Production Example 1 was put into a rotary flow coating device (MP-01), and spray mist of the prescription shown in Table 49 was sprayed. Then, it dried to obtain 533.3 g of mulch. Corresponds to 1.4 of the obtained coverings with 1g coverings After adding an ethanol/water mixed solution (6:4) in a ratio of mL, it was molded using a low-pressure molding machine and dried to obtain tablets with a diameter of 12 mm.

表50示出覆蓋品的回收率。使用X射線CT顯微鏡對獲得的片劑進行解析後,獲得表54所示片劑的體積率及表55所示片劑內添加劑體積率的結果。 Table 50 shows the recovery rate of the covering product. After analyzing the obtained tablets using an X-ray CT microscope, the results of the volume ratio of the tablets shown in Table 54 and the volume ratio of additives in the tablets shown in Table 55 were obtained.

Figure 106110616-A0202-12-0052-49
Figure 106110616-A0202-12-0052-49

Figure 106110616-A0202-12-0052-50
Figure 106110616-A0202-12-0052-50

《實施例26》 "Example 26"

將製造例1中獲得的500g球狀活性炭投入轉動流動鍍膜裝置(MP-01),噴出表51所示處方的噴液霧。然後,進行乾燥,獲得520.7g覆蓋品。向獲得的覆蓋品中以1g覆蓋品對應0.9 mL的比例添加乙醇/水混合液(2:8)後,使用低壓成型機進行成型,並進行乾燥,從而獲得直徑12mm的片劑。 500 g of spherical activated carbon obtained in Production Example 1 was put into a rotary flow coating device (MP-01), and a spray mist of the prescription shown in Table 51 was sprayed. Then, it dried to obtain 520.7 g of mulch. Corresponds to 0.9 for 1g of the obtained coverings After adding an ethanol/water mixture (2:8) in a ratio of mL, molding was performed using a low-pressure molding machine and dried to obtain tablets with a diameter of 12 mm.

表52示出覆蓋品的回收率。使用X射線CT顯微鏡對獲得的片劑進行解析後,獲得表54所示片劑的體積率及表55所示片劑內添加劑體積率的結果。 Table 52 shows the recovery rate of the cover product. After analyzing the obtained tablets using an X-ray CT microscope, the results of the volume ratio of the tablets shown in Table 54 and the volume ratio of additives in the tablets shown in Table 55 were obtained.

Figure 106110616-A0202-12-0053-51
Figure 106110616-A0202-12-0053-51

Figure 106110616-A0202-12-0053-52
Figure 106110616-A0202-12-0053-52

《比較例1》 "Comparative Example 1"

使製造例1中獲得的500g球狀活性炭裝入攪拌造粒機(VG-01)中,一邊攪拌一邊添加將25g普魯蘭多糖溶解於600mL精製水中得到的溶液,且進行5分鐘,然後捏合10分鐘,回收捏合物。表53示出捏合物的回收率。 500g of spherical activated carbon obtained in Production Example 1 was charged into a stirring granulator (VG-01), and a solution obtained by dissolving 25g of pullulan in 600mL of purified water was added while stirring, and then kneaded for 5 minutes After 10 minutes, the kneaded product was recovered. Table 53 shows the recovery rate of the kneaded product.

《比較例2》 "Comparative Example 2"

使製造例1中獲得的20g球狀活性炭、1.2g普魯蘭多糖及0.18g月桂基硫酸鈉在燒杯內均勻分散,然後添加24mL精製水。使用抹刀將獲得的混合物捏合,避免添加劑結塊。將調製的捏合物(糊狀物)填充到成型模具(直徑12mm、深度10.2mm),用抹刀刮平,用上部安裝到攪拌機的成型棒輕輕壓縮,修整片劑表面。對各成型模具進行乾燥,從而獲得片劑。使用X射線CT顯微鏡對獲得的片劑進行解析後,獲得表54所示片劑的體積率及表55所示片劑內添加劑體積率的結果。 20 g of spherical activated carbon, 1.2 g of pullulan, and 0.18 g of sodium lauryl sulfate obtained in Production Example 1 were uniformly dispersed in a beaker, and then 24 mL of purified water was added. Use a spatula to knead the obtained mixture to avoid agglomeration of additives. The prepared kneaded mixture (paste) was filled into a molding die (diameter 12mm, depth 10.2mm), scraped flat with a spatula, and lightly compressed with a molding rod attached to the mixer to trim the surface of the tablet. Each molding die is dried to obtain tablets. After analyzing the obtained tablets using an X-ray CT microscope, the results of the volume ratio of the tablets shown in Table 54 and the volume ratio of additives in the tablets shown in Table 55 were obtained.

《比較例3》 "Comparative Example 3"

使製造例1中獲得的20g球狀活性炭、9.36g普魯蘭多糖及1.40g月桂基硫酸鈉在燒杯內均勻分散,然後添加28mL精製水。使用抹刀將獲得的混合物捏合,避免添加劑結塊。將調製的捏合物(糊狀物)填充到成型模具(直徑12mm、深度10.2mm),用抹刀刮平,用上部安裝到攪拌機的成型棒輕輕壓縮,修整片劑表面。對各成型模具進行乾燥,從而獲得片劑。使用X射線CT顯微鏡對獲得的片劑進行解析後,獲得表55所示片劑內添加劑體積率的結果。 20 g of spherical activated carbon, 9.36 g of pullulan and 1.40 g of sodium lauryl sulfate obtained in Production Example 1 were uniformly dispersed in a beaker, and then 28 mL of purified water was added. Use a spatula to knead the obtained mixture to avoid agglomeration of additives. The prepared kneaded mixture (paste) was filled into a molding die (diameter 12mm, depth 10.2mm), scraped flat with a spatula, and lightly compressed with a molding rod attached to the mixer to trim the surface of the tablet. Each molding die is dried to obtain tablets. After analyzing the obtained tablets using an X-ray CT microscope, the results of the volume ratio of additives in the tablets shown in Table 55 were obtained.

Figure 106110616-A0202-12-0055-53
Figure 106110616-A0202-12-0055-53

在比較例1的捏合法中,如圖5所示,球狀活性炭殘留於混合機上、或者附著於成型模具上,因而收穫率為87.8%,而在實施例1的本發明的製造方法中,球狀活性炭的收穫率為100.2%,得到飛躍性改善。 In the kneading method of Comparative Example 1, as shown in FIG. 5, the spherical activated carbon remained on the mixer or adhered to the molding die, so the yield was 87.8%. However, in the manufacturing method of the present invention of Example 1, , The harvest rate of spherical activated carbon is 100.2%, which is a drastic improvement.

《使用X射線CT顯微鏡的片劑的體積率的解析》 "Analysis of the Volume Ratio of Tablets Using X-ray CT Microscopes"

使用X射線CT顯微鏡nano3DX(理學株式會社)用以下條件對實施例1中獲得的2個批次的片劑、以及比較例2中獲得的3個批次的片劑的內部進行解析。 The insides of the two batches of tablets obtained in Example 1 and the three batches of tablets obtained in Comparative Example 2 were analyzed under the following conditions using an X-ray CT microscope nano3DX (Rigaku Corporation).

線源:Mo Line source: Mo

電壓:50kV Voltage: 50kV

電流:24mA Current: 24mA

像素尺寸:8.64μm/voxel Pixel size: 8.64μm/voxel

拍攝張數:1200張 Number of shots: 1200

拍攝時間:約3小時 Shooting time: about 3 hours

使用附帶的解析軟體,求出分割為3部分的片劑的上部、中部、及下部的邊長2mm的立方體的體積率。比較例2中獲得的3 個批次的片劑的3個立方體的體積率之相對標準偏差(RSD)高達5.5%、7.1%以及5.3%。另一方面,實施例1中獲得的2個批次的片劑的3個立方體的體積率的RSD為1.0%及2.4%,本發明的片劑具有較好的均勻性(表54)。 Using the attached analysis software, the volume ratio of a cube with a side length of 2 mm in the upper, middle, and lower parts of the tablet divided into three parts was calculated. 3 obtained in Comparative Example 2 The relative standard deviations (RSD) of the volume ratios of 3 cubes of tablets of each batch are as high as 5.5%, 7.1% and 5.3%. On the other hand, the RSD of the volume ratio of the 3 cubes of the 2 batches of tablets obtained in Example 1 were 1.0% and 2.4%, and the tablet of the present invention had good uniformity (Table 54).

使用X射線CT顯微鏡TDM1000H-II(2K)(大和科學株式會社)用以下條件對實施例2至實施例26中獲得的各1個批次的片劑的內部進行解析。 Using an X-ray CT microscope TDM1000H-II (2K) (Daiwa Scientific Co., Ltd.), the inside of each batch of tablets obtained in Example 2 to Example 26 was analyzed under the following conditions.

線源:W Line source: W

電壓:50kV(實施例2至實施例26) Voltage: 50kV (Example 2 to Example 26)

電流:0.080A(實施例2)、0.085mA(實施例3至實施例26) Current: 0.080A (Example 2), 0.085mA (Example 3 to Example 26)

像素尺寸:17.5μm/voxel(實施例2)、12.7μm/voxel(實施例3至實施例26) Pixel size: 17.5μm/voxel (Example 2), 12.7μm/voxel (Example 3 to Example 26)

拍攝張數:700至1500張(根據片劑厚度任意設定) Number of shots: 700 to 1500 (arbitrarily set according to the thickness of the tablet)

拍攝時間:20分鐘(實施例2)、10分鐘(實施例3至實施例26) Shooting time: 20 minutes (Example 2), 10 minutes (Example 3 to Example 26)

使用解析軟體ImageJ,求出分割為3部分的片劑的上部、中部、及下部的邊長2mm的立方體的體積率。根據獲得的圖像中的256級的亮度信息,透過基於大津的方法的自動閾值計算而將球狀活性炭以及添加劑與空隙分開,將該圖像積算相當於2mm厚度的數量時的球狀活性炭以及添加劑的像素數的比例設為體積率(表54)。 Using the analysis software ImageJ, the volume ratio of a cube with a side length of 2 mm in the upper, middle, and lower parts of the tablet divided into three parts was obtained. According to the 256-level brightness information in the obtained image, the spherical activated carbon and additives are separated from the voids through automatic threshold calculation based on Otsu’s method, and the spherical activated carbon and the spherical activated carbon and the amount equivalent to the thickness of 2mm are accumulated in the image. The ratio of the number of pixels of the additive was defined as the volume ratio (Table 54).

Figure 106110616-A0202-12-0057-54
Figure 106110616-A0202-12-0057-54

《使用X射線CT顯微鏡的片劑的添加劑體積率的解析》 "Analysis of Additive Volume Rate of Tablets Using X-ray CT Microscope"

使用X射線CT顯微鏡TDM1000H-II(2K)(大和科學株式會社)用以下條件對實施例1至實施例26中獲得的片劑、以及比較例2、3中獲得的片劑的內部進行解析。 The insides of the tablets obtained in Examples 1 to 26 and the tablets obtained in Comparative Examples 2 and 3 were analyzed using the X-ray CT microscope TDM1000H-II (2K) (Daiwa Scientific Co., Ltd.) under the following conditions.

線源:W Line source: W

電壓:40kV(實施例1、比較例2)、50kV(實施例2至實施例26、比較例3) Voltage: 40kV (Example 1, Comparative Example 2), 50kV (Example 2 to Example 26, Comparative Example 3)

電流:0.095mA(實施例1、比較例2)、0.080mA(實施例2、比較例3)、0.085mA(實施例3至實施例26) Current: 0.095mA (Example 1, Comparative Example 2), 0.080mA (Example 2, Comparative Example 3), 0.085mA (Example 3 to Example 26)

像素尺寸:15.9μm/voxel(實施例1)、14.4μm/voxel(比較例2)、17.5μm/voxel(實施例2、比較例3)、12.7μm/voxel(實施例3至實施例26) Pixel size: 15.9μm/voxel (Example 1), 14.4μm/voxel (Comparative Example 2), 17.5μm/voxel (Example 2, Comparative Example 3), 12.7μm/voxel (Example 3 to Example 26)

拍攝張數:700至1500張(根據片劑厚度任意設定) Number of shots: 700 to 1500 (arbitrarily set according to the thickness of the tablet)

拍攝時間:30分鐘(實施例1、比較例2)、20分鐘(實施例2、比較例3)、10分鐘(實施例3至實施例26) Shooting time: 30 minutes (Example 1, Comparative Example 2), 20 minutes (Example 2, Comparative Example 3), 10 minutes (Example 3 to Example 26)

使用解析軟體ImageJ對實施例1、實施例3至實施例26以及比較例2的各1個片劑、實施例2以及比較例3的各3各片劑,計算圖3的C、N、E、S、以及W的5個棱柱的添加劑的體積率。根據獲得的圖像的256級亮度的訊息,球狀活性炭對應亮度的像素數的分佈呈正規分佈,因此將該亮度的平均值加上標準偏差2.5倍所得值以上的亮度的部分定義為添加劑,將該像素數的比例設為添加劑面積率,將按指定厚度對應的數量累計該圖像時的添加劑的像 素數的比例設為添加劑體積率(圖6)。各棱柱的添加劑體積率的最大值與最小值的值、以及5個棱柱的最大值與最小值的比值如表55所示。此外,比較例2的位置C的添加劑面積率及體積率的從上面到下面的變動如圖4所示。 The analysis software ImageJ was used to calculate the C, N, and E of FIG. 3 for each 1 tablet of Example 1, Example 3 to Example 26, and Comparative Example 2, and each of 3 tablets of Example 2 and Comparative Example 3. The volume ratio of the additives of 5 prisms of, S, and W. According to the 256-level brightness information of the obtained image, the distribution of the number of pixels corresponding to the brightness of the spherical activated carbon is a regular distribution. Therefore, the average value of the brightness plus the standard deviation of 2.5 times or more of the brightness is defined as an additive. The ratio of the number of pixels is set as the additive area ratio, and the image of the additive when the image is accumulated by the number corresponding to the specified thickness The ratio of prime numbers was set as the additive volume ratio (Figure 6). Table 55 shows the maximum and minimum values of the additive volume rate of each prism, and the ratio of the maximum and minimum values of the five prisms. In addition, the change in the area ratio and volume ratio of the additive at the position C of Comparative Example 2 from the top to the bottom is shown in FIG. 4.

如圖4所示,用過去的捏合法獲得的片劑的添加劑體積率在片劑的上面到下面之間發生巨大變動。 As shown in Fig. 4, the additive volume ratio of the tablet obtained by the past kneading method varies greatly from the top to the bottom of the tablet.

Figure 106110616-A0202-12-0059-55
Figure 106110616-A0202-12-0059-55
Figure 106110616-A0202-12-0060-56
Figure 106110616-A0202-12-0060-56

Claims (1)

一種片劑的製造方法,其係含有添加劑、以及口服給藥用球狀吸附炭之片劑的製造方法,其特徵在於,用X射線CT顯微鏡對從上面觀察所述片劑時的中心部、以及位於從中心向四方延伸的直線端部的從上面到下面的邊長1mm的5個棱柱的添加劑的體積率從上面到下面進行解析時,5個棱柱的每1mm3的添加劑體積率的最大值及最小值的比值為100以下,在將所述片劑的扁平方向長度分割成3等分的各分割體中,用X射線CT顯微鏡對位於扁平方向長度的中央且位於從上面觀察的片劑中心的邊長2mm立方體的體積率進行解析時,3個分割體的立方體的體積率的相對標準偏差為5%以下,所述添加劑相對於所述口服給藥用球狀吸附炭為1~35重量%,且所述片劑的製造方法包含下述製程:(1)將包含選自由藻酸鈉、藻酸丙二醇酯、羧甲基纖維素鈣、茄替膠、角叉菜膠、羧基乙烯聚合物、羧甲基纖維素鈉、黃原膠、瓜爾豆膠、榅桲籽膠、葡甘露聚糖、共聚維酮、結蘭膠、明膠、羅望子膠、他拉膠、葡聚糖、玉米澱粉、黃蓍膠、透明質酸鈉、羥乙基纖維素、羥丙澱粉、羥丙基纖維素、羥丙甲纖維素、普魯蘭多糖、聚維酮、聚環氧乙烷、聚乙烯醇、聚乙烯醇-丙烯酸-甲 基丙烯酸甲酯共聚物、聚乙烯二醇6000、乙基纖維素、磷酸交聯澱粉、刺槐豆膠、瓊脂、寒梅粉、完全預膠化澱粉、結晶纖維素甲基纖維素鈉、氧化澱粉、低取代度羥丙基纖維素、部分預膠化澱粉以及糖類所組成的群組中的黏合用添加劑的溶液噴到口服給藥用球狀吸附炭上,用黏合用添加劑覆蓋口服給藥用球狀吸附炭的製程;(2)向被覆蓋的所述口服給藥用球狀吸附炭添加溶媒,然後通過壓縮成型,獲得成型體的壓縮成型製程;以及(3)對獲得的成型體進行乾燥的製程。 A method for manufacturing a tablet, which is a method for manufacturing a tablet containing additives and spherical adsorption carbon for oral administration, characterized in that the center part of the tablet when viewed from above with an X-ray CT microscope, And the additive volume ratio of 5 prisms with a side length of 1mm from top to bottom at the end of a straight line extending from the center to the four directions. When analyzed from top to bottom, the volume ratio of the additive per 1mm 3 of the 5 prisms is the largest The ratio of the value to the minimum value is 100 or less. In each divided body that divides the length in the flat direction of the tablet into three equal parts, an X-ray CT microscope is used to examine the slice located at the center of the length in the flat direction and viewed from above. When the volume ratio of a cube with a side length of 2 mm at the center of the agent is analyzed, the relative standard deviation of the volume ratio of the cube of the three divided bodies is 5% or less, and the additive is 1 to 1 to the spherical adsorption carbon for oral administration. 35 wt%, and the manufacturing method of the tablet includes the following process: (1) will contain selected from sodium alginate, propylene glycol alginate, calcium carboxymethyl cellulose, gum ghatti, carrageenan, carboxyl Ethylene polymer, sodium carboxymethyl cellulose, xanthan gum, guar gum, quince seed gum, glucomannan, copovidone, gellan gum, gelatin, tamarind gum, tara gum, dextran Sugar, corn starch, tragacanth, sodium hyaluronate, hydroxyethyl cellulose, hydroxypropyl starch, hydroxypropyl cellulose, hypromellose, pullulan, povidone, polyethylene oxide , Polyvinyl alcohol, polyvinyl alcohol-acrylic acid-methyl methacrylate copolymer, polyethylene glycol 6000, ethyl cellulose, phosphoric acid cross-linked starch, locust bean gum, agar, winter plum powder, fully pregelatinized starch, A solution of adhesive additives in the group consisting of crystalline cellulose methylcellulose sodium, oxidized starch, low-substituted hydroxypropyl cellulose, partially pregelatinized starch, and sugars is sprayed onto spherical adsorption charcoal for oral administration Above, the process of covering the spherical adsorbent carbon for oral administration with adhesive additives; (2) Adding a solvent to the covered spherical adsorbent carbon for oral administration, and then compressing and molding to obtain a compression molding process And (3) the process of drying the obtained molded body.
TW106110616A 2016-04-01 2017-03-29 Tablet containing spherical adsorption carbon for oral administration and its manufacturing method TWI701055B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2016074580 2016-04-01
JP2016-074580 2016-04-01

Publications (2)

Publication Number Publication Date
TW201735906A TW201735906A (en) 2017-10-16
TWI701055B true TWI701055B (en) 2020-08-11

Family

ID=59964672

Family Applications (1)

Application Number Title Priority Date Filing Date
TW106110616A TWI701055B (en) 2016-04-01 2017-03-29 Tablet containing spherical adsorption carbon for oral administration and its manufacturing method

Country Status (5)

Country Link
JP (1) JP6707126B2 (en)
KR (1) KR20180118784A (en)
CN (1) CN108883130B (en)
TW (1) TWI701055B (en)
WO (1) WO2017170764A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111408343B (en) * 2019-01-08 2022-01-28 湖南农业大学 Preparation method of three-dimensional biochar and application of three-dimensional biochar in heavy metal adsorption
JP7438897B2 (en) 2020-08-26 2024-02-27 フタムラ化学株式会社 Tablet type adsorbent for oral administration

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006036734A (en) * 2004-07-30 2006-02-09 Toa Eiyo Ltd Activated carbon product for oral administration
TW201249478A (en) * 2011-03-04 2012-12-16 Kureha Corp Tablet-formed pharmaceutical composition for oral administration and method for preparing the same

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5595611A (en) * 1979-01-17 1980-07-21 Osamu Otsubo Mannan-coated activated carbon
DE3572440D1 (en) * 1984-06-19 1989-09-28 Basf Ag Gastro-resistant cylindrical pancreatine-microtablets
US6294198B1 (en) * 1999-08-24 2001-09-25 Purepac Pharmaceutical Co. Pharmaceutical tablet formulation containing gabapentin with improved physical and chemical characteristics and method of making the same
JP2005187405A (en) * 2003-12-25 2005-07-14 Lion Corp Uric acid value inhibitor and purine body adsorbent
JP2007137802A (en) * 2005-11-16 2007-06-07 Takeda Chem Ind Ltd Method for producing tablet
CN101103997B (en) * 2006-09-05 2011-02-02 河北长天药业有限公司 Colored medicinal charcoal film coated tablet preparation method
CN101543511A (en) * 2008-03-26 2009-09-30 河北长天药业有限公司 Pressed pharmaceutical composition containing medicinal charcoal and polyethyleneglycol
JP5415837B2 (en) * 2009-06-12 2014-02-12 アサヒグループホールディングス株式会社 Method for producing granules and tablets from a powdery functional substance having inferior compression moldability
JP6310780B2 (en) * 2013-06-12 2018-04-11 第一三共ヘルスケア株式会社 Oral composition

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006036734A (en) * 2004-07-30 2006-02-09 Toa Eiyo Ltd Activated carbon product for oral administration
TW201249478A (en) * 2011-03-04 2012-12-16 Kureha Corp Tablet-formed pharmaceutical composition for oral administration and method for preparing the same

Also Published As

Publication number Publication date
TW201735906A (en) 2017-10-16
JPWO2017170764A1 (en) 2018-12-27
WO2017170764A1 (en) 2017-10-05
KR20180118784A (en) 2018-10-31
JP6707126B2 (en) 2020-06-10
CN108883130A (en) 2018-11-23
CN108883130B (en) 2021-06-22

Similar Documents

Publication Publication Date Title
JP5701971B2 (en) Tablet-type composition for oral administration and method for producing the same
TWI600665B (en) Low-substituted hydroxypropyl cellulose powder and its production method
KR101815722B1 (en) Tolvaptan solid dispersion and its preparation method
TWI701055B (en) Tablet containing spherical adsorption carbon for oral administration and its manufacturing method
JP2023182650A (en) Granular composition, method for producing granular composition, and method for improving elution property of granular composition
CN103110595B (en) Cefdinir dispersible tablet and preparation method thereof
JP2002104956A (en) Base for dry direct compressing hydroxypropylcellulose having low substitution degree
KR20050039732A (en) Method for the formation of ibuprofen crystals
TWI693946B (en) Lozenges containing spherical carbon for oral administration
CN103655501A (en) Nano ibuprofen dry powder, tablets and preparation method thereof
JP2011530529A (en) Sustained release composition comprising gum and sugar alcohol
US7009046B2 (en) Low-substituted hydroxypropyl cellulose and agent serving both as binder and disintegrant for dry direct compression
WO2008145361A1 (en) Mineral-fiber solid dispersion, method for preparing the same, and use thereof as pharmaceutical tableting aid
JPH05139973A (en) Production of nifedipin-containing solid preparation
KR101509489B1 (en) Method for preparing solid oral formulation comprising valsartan
JP5910255B2 (en) Dioctyl sodium sulfosuccinate solid formulation
WO2023158411A1 (en) A tablet of tolvaptan and at least one binder processed with wet granulation
WO2004089344A1 (en) Process for producing tablet
CN1313087C (en) Preparation method for increasing dissolution of sofalcone
EP4321154A1 (en) A tablet of tolvaptan and at least one binder processed with spray granulation
JP6216408B2 (en) Method for preparing very poorly soluble drugs in solid dosage forms
WO2024030098A1 (en) A tablet of tolvaptan and at least one binder processed with spray granulation
TWI523842B (en) Tolvaptan solid dispersion and its preparation method
CN116370417A (en) Rasagiline granule composition and pharmaceutical composition thereof
JP2003119121A (en) Method for producing tablet